Methods and reagents for detecting mammalian antibodies

By detecting mammalian antibodies that specifically bind ZSCAN5, using ZSCAN5 polypeptide to immobilize the carrier to contact the sample and isolate the antibodies, solving the problem of early diagnosis of neuronal autoimmune diseases and cancer in the prior art, and improving diagnosis The reliability and sensitivity of the system provide diagnostic tools for treatment and monitoring.

CN119064588APending Publication Date: 2024-12-03EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA +1

Patent Information

Application Number
CN202410695359.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2024-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively diagnose neuronal autoimmune diseases and cancers, especially due to the lack of specific clinical symptoms patterns and detection methods, which lead to difficulty in early diagnosis, and many diagnostic-related antibodies are unknown, resulting in high risk of misdiagnosis and undiagnosis.

Method used

By detecting mammalian antibodies specifically binding to ZSCAN5, immobilizing on the carrier with a polypeptide containing ZSCAN5 or a variant thereof, and contacting the sample, isolating and detecting the antibody, providing a method for diagnosing and distinguishing caused by ZSCAN5 antibodies Diseases and other factors lead to illness.

Benefits of technology

Improves the diagnostic reliability and sensitivity of neuronal autoimmune diseases and cancers, can distinguish diseases caused by ZSCAN5 antibodies from diseases caused by other factors, and provides diagnostic tools for treatment and monitoring.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004869538250000781
    Figure BDA0004869538250000781
  • Figure BDA0004869538250000791
    Figure BDA0004869538250000791
  • Figure BDA0004869538250000801
    Figure BDA0004869538250000801
Patent Text Reader

Abstract

The present invention relates to a method comprising a step of detecting a mammalian antibody specifically binding to ZSCAN5 in a sample, a mammalian antibody specifically binding to ZSCAN5, a carrier having a solid phase with at least one immobilized polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof, and the use of a mammalian antibody for diagnosing a neurological autoimmune disease or cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method comprising the step of detecting mammalian antibodies that specifically bind to ZSCAN5 in a sample, mammalian antibodies that specifically bind to ZSCAN5, a carrier having a solid phase, the solid phase having at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof, and use of the mammalian antibodies for diagnosing neurological autoimmune diseases or cancer. Background Art

[0002] Neurological autoimmune diseases are rare but potentially treatable. They are marked by the development of neurological symptoms and an autoimmune response, often associated with the development of antibodies that specifically bind to structures in the brain, such as polypeptides that have important functions in neurotransmission. They may affect any area of ​​the nervous system, including the central, peripheral, and autonomic nervous systems. Although system involvement is often multifocal, as in encephalomyelitis, it may also involve a single system, such as cerebellar degeneration.

[0003] Neurological autoimmune diseases may be associated with cancer. If this is the case, it may be referred to as PNS (paraneoplastic syndrome). Neurological symptoms appear before or after the cancer diagnosis, although in some cases, no primary cancer is found even at autopsy. Most PNS reflect a specific autoimmune attack on the nervous system triggered by tumor neural antigens released into the peripheral lymphoid tissues by an unsuspected primary or recurrent tumor. Typically, cerebrospinal fluid (CSF) studies in these patients show lymphocytosis, elevated protein, increased IgG synthesis, and increased oligoclonal bands, supporting immunopathology. Antibodies that bind specifically to accessible membrane targets directly cause the disease, as in the case of antibodies to acetylcholine receptors in myasthenia gravis and P / Q-type voltage-gated calcium channels in Lambert Eaton myasthenic syndrome. Often, cancer is asymptomatic when the neurological syndrome presents. Some paraneoplastic antibodies are specifically associated with cancer, others are not.

[0004] The discovery that neuropsychiatric symptoms, including recurrent seizures, cognitive and behavioral impairments, are associated with distinct autoantibodies has radically improved the diagnostic and therapeutic approaches for several severe neurological diseases, including the spectrum of encephalitis, including limbic encephalitis (LE) and autoimmune encephalitis. Autoantibodies that specifically bind to neuronal surface proteins, such as NMDAR, AMPAR, mGluR5, GABABR, DPPX or LGl1, and tumor neural targets, including GAD65, PNMA2 and BMPER, and amphiphysin, targeting intracellular protein structures, have been found to be associated with encephalitis.

[0005] Early diagnosis and treatment of neurological autoimmune diseases are extremely important, as any delay can result in rapidly progressive and irreversible neurological damage. In contrast, early and appropriate treatment, usually with some form of immunosuppressive therapy, may reverse some of the damage and, in some cases, even lead to full recovery. For example, 80% of patients with NMDA receptor (NMDAR) encephalitis have a good prognosis after immunosuppressive therapy, but may also experience long-term psychiatric problems or relapses.

[0006] However, diagnosing neurological autoimmune diseases is often difficult. One reason is the lack of a specific clinical symptom pattern and the absence of specific imaging and laboratory abnormalities. For example, despite progress in identifying autoantibody-mediated immune mechanisms in a significant proportion (>50%) of patients with encephalitis, especially suspected LE, specific “neurological” antibodies cannot be detected. Even after extensive evaluation for infectious etiologies, approximately 70% of encephalitis cases of unknown etiology remain undiagnosed. A better understanding of the immune mechanisms in patients with seronegative encephalitis may open up new treatment options for affected individuals.

[0007] Treatment of the underlying cancer (if present) is very important for the treatment of neurological conditions and is often crucial to the patient's survival rate. However, 30-40% of patients with suspected or presumed PNS will not present any antibodies that can be detected by state-of-the-art testing, as many diagnostically relevant autoantibodies remain unknown. There remains a high risk that these patients remain undiagnosed or even misdiagnosed. Summary of the invention

[0008] The present invention is based on the surprising discovery of the inventors that mammalian antibodies against ZSCAN5 are present and can be detected in samples from patients suffering from neurological autoimmune diseases and / or cancer, but not in samples from healthy subjects.

[0009] Therefore, the problem underlying the present invention is to provide reagents and methods for the diagnosis and treatment of autoimmune diseases such as neurological autoimmune diseases and / or cancer, preferably associated with the presence of mammalian antibodies that specifically bind to ZSCAN5, and for the manufacture of diagnostic and therapeutic products.

[0010] Another problem of the present invention is to distinguish autoimmune diseases caused by mammalian antibodies that specifically bind to ZSCAN5 from diseases caused by other factors (especially infections). Other factors that cause diseases that can be distinguished from autoimmune diseases based on the present invention include alcohol or drug abuse and psychiatric conditions that are not caused by the presence of the antibodies of the present invention.

[0011] A further problem of the present invention was to provide an assay with increased diagnostic reliability, in particular in terms of specificity and / or sensitivity, for diagnosing autoimmune diseases, such as neurological autoimmune diseases, or cancer, preferably PNS and / or LE, optionally in combination with assays from the prior art.

[0012] The problem underlying the invention is solved by the subject matter of the enclosed independent and dependent claims.

[0013] In a first aspect, the problem of the present invention is solved by a method comprising the step of detecting mammalian antibodies that specifically bind to ZSCAN5 in a sample.

[0014] In a second aspect, the problem of the present invention is solved by a method for isolating mammalian antibodies that specifically bind to ZSCAN5, the method comprising the following steps:

[0015] a) immobilizing at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof on a carrier,

[0016] b) contacting a sample comprising the antibody with said at least one polypeptide under conditions compatible with formation of a complex, wherein said antibody binds to said polypeptide,

[0017] c) separating the complex formed in step a) from the sample,

[0018] d) optionally separating the antibody from the polypeptide, and

[0019] e) optionally detecting the antibody or complex.

[0020] In a third aspect, the problem of the invention is solved by a method comprising the following steps:

[0021] contacting a polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof with a liquid comprising a mammalian antibody that specifically binds to ZSCAN5, wherein a candidate drug is present and / or the liquid does not contain a sample from a subject to be diagnosed, and

[0022] Binding of the antibody is preferably detected in a quantitative manner.

[0023] In a preferred embodiment, the method comprises the step of immobilizing a polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof on a carrier, preferably before contacting the polypeptide with a liquid. In another preferred embodiment, the candidate drug is present in a liquid and / or is contacted with an antibody before contacting the polypeptide with a liquid.

[0024] In a fourth aspect, the problem is solved by a mammalian antibody that specifically binds to ZSCAN5, preferably in a liquid comprising one or more, more preferably all, selected from the group comprising an artificial buffer, a preservative and an artificial anticoagulant and / or selected from the group comprising blood, such as whole blood, plasma, serum and CSF, optionally wherein the liquid is diluted.

[0025] In a fifth aspect, the problem is solved by providing a carrier, preferably a diagnostically useful carrier, comprising a solid phase, the solid phase comprising at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof, preferably an immobilized polypeptide, and a) a negative control and / or a positive control and / or b) at least one further antigen, preferably a diagnostically useful antigen, preferably wherein the at least one polypeptide and the negative control and / or the positive control or the further antigen are spatially separated on the carrier or a first carrier, preferably a first diagnostically useful carrier, which has a solid phase, the solid phase comprising at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof, preferably an immobilized polypeptide, and a second carrier, preferably a second diagnostically useful carrier, which comprises a solid phase comprising immobilized a) negative control and / or positive control and / or b) at least one further polypeptide comprising an immobilized antigen or a variant thereof.

[0026] In a preferred embodiment, the at least one additional antigen is selected from NMDAR, LgI1, AMPA1, AMPA2, CASPR2, GABA B, GABA A, DPPX, IGLON5, Hu, Yo, CV2 / CRMP5, Ri, Ma2, amphotericin, Recoverin, RGS8, DAGLA, STX1B, AK5, AP3B2, Flotillin 1+2, GRM1, GRM2, GRM5, GLURD2, ITPR1, KCNA2, NCDN, Septin 3+5+6+7+11 and Sez6L2 or variants thereof, preferably all antigens.

[0027] In a sixth aspect, the problem is solved by a kit comprising at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof and a carrier, preferably a diagnostically useful carrier, more preferably a carrier according to the invention, wherein:

[0028] a) immobilizing the at least one polypeptide on a support, preferably a diagnostically useful support, more preferably a support according to the present invention, and the kit further comprises means for detecting mammalian antibodies, preferably specifically binding to ZSCAN5,

[0029] b) the at least one polypeptide and the carrier are configured to immobilize the at least one polypeptide on the surface of the carrier, preferably via an affinity tag and a ligand that binds to the affinity tag, and the kit further comprises means for detecting mammalian antibodies (preferably specifically binding to ZSCAN5),

[0030] c) the carrier is immobilized with means for capturing antibodies, and the kit further comprises means for detecting mammalian antibodies, preferably comprising at least one detectably labeled polypeptide, or

[0031] d) the support and the means for capturing antibodies are configured to immobilize the means for capturing antibodies on the surface of the support, preferably via an affinity tag and a ligand that binds to the affinity tag, and the kit further comprises means for detecting mammalian antibodies, preferably comprising at least one detectably labeled polypeptide,

[0032] And preferably one or more selected from a recombinant antibody that binds to ZSCAN5, a mammalian antibody that binds to ZSCAN5, a chemical solution that reacts with a detectable label, a positive control, a negative control, a waterproof container for incubating a sample with a carrier or a reagent, a sample dilution buffer, a washing buffer, and a calibrator, preferably a set of calibrators, more preferably all.

[0033] In a seventh aspect, the problem is solved by the use of a) a mammalian antibody that specifically binds to ZSCAN5 or a variant thereof, or b) at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof in combination with means for detecting the mammalian antibody, or c) a carrier according to the invention, or d) a kit according to the invention for identifying patients with an increased risk of suffering from or developing a disease associated with the presence of a mammalian antibody that specifically binds to ZSCAN5 and / or for diagnosing a neurological autoimmune disease or cancer.

[0034] In an eighth aspect, the problem is solved by the use of at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof, or a mammalian antibody that specifically binds to ZSCAN5 or a variant thereof, or a recombinant antibody that specifically binds to ZSCAN5 or a variant thereof for the manufacture of a kit, preferably an analytical kit, or a medical device, preferably a diagnostic device, optionally for the diagnosis of a disease or for aiding the diagnosis of a disease.

[0035] In a ninth aspect, the problem is solved by the use of a mammalian antibody that specifically binds to ZSCAN5 or a variant thereof, or a recombinant antibody that specifically binds to ZSCAN5 or a variant thereof as a positive control for detecting antibodies that specifically bind to ZSCAN5 or a variant thereof in a sample, wherein the antibody is preferably recognized by a secondary antibody against human IgG class immunoglobulins.

[0036] In a tenth aspect, the problem is solved by an ex vivo method for removing antibodies specifically binding to ZSCAN5 or a variant thereof from blood, preferably blood of a mammalian patient, or preferably serum of a mammalian patient.

[0037] In the eleventh aspect, the problem is solved by a method for diagnosing a disease or for assisting in the diagnosis of a disease, the disease being associated with a mammalian antibody that specifically binds to ZSCAN5 or a variant thereof, such as an autoimmune disease, preferably a neurological autoimmune disease. In one embodiment, the method for diagnosing a disease or for assisting in the diagnosis of a disease is an in vivo method. In one embodiment, the method for diagnosing a disease or for assisting in the diagnosis of a disease is an ex vivo method. In one embodiment, the method for diagnosing a disease or for assisting in the diagnosis of a disease comprises the use of at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof. In one embodiment, the disease is an autoimmune disease, preferably a neurological autoimmune disease, such as those described herein, and / or cancer, such as those described herein. In one embodiment, the method for diagnosing a disease or for assisting in the diagnosis of a disease comprises a step of detecting a mammalian antibody that specifically binds to ZSCAN5 or a variant thereof from blood, preferably blood of a mammalian patient, or preferably serum of a patient.

[0038] In one embodiment, ZSCAN5 comprises at least one zinc finger domain and at least one SCAN oligomerization domain. In a preferred embodiment, ZSCAN5 comprises one or more, preferably all, amino acid sequences selected from the group comprising SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 or variants thereof. In one embodiment, ZSCAN5 comprises 1, 2, 3 or 4 amino acid sequences selected from the group comprising SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 or variants thereof. Preferably, ZSCAN5 is represented by ZSCAN5A, ZSCAN5B and / or ZSCAN5C. In one embodiment, ZSCAN5 is represented by ZSCAN5A, wherein the protein optionally comprises the amino acid sequence as shown in SEQ ID NO: 5 or variants thereof. In one embodiment, ZSCAN5 is ZSCAN5B, wherein the protein optionally comprises the amino acid sequence as shown in SEQ ID NO: 6 or variants thereof. In one embodiment, ZSCAN5 is ZSCAN5C, wherein the protein optionally comprises the amino acid sequence as shown in SEQ ID NO: 7 or variants thereof. Preferably, ZSCAN5 comprises an amino acid sequence as shown in SEQ ID NO: 8 or a variant thereof. In one embodiment, ZSCAN5 comprises one or more amino acid sequences selected from the group comprising SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17 or variants thereof. In one embodiment, ZSCAN5 comprises one or more amino acid sequences selected from the group comprising SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20 or variants thereof. In one embodiment, ZSCAN5 comprises one or more amino acid sequences selected from the group comprising SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24 or variants thereof.

[0039] In one embodiment, a mammalian antibody that binds to ZSCAN5 binds to ZSCAN5A or a variant thereof. In one embodiment, a mammalian antibody that binds to ZSCAN5 binds to ZSCAN5B or a variant thereof. In one embodiment, a mammalian antibody that binds to ZSCAN5 binds to ZSCAN5C or a variant thereof. In one embodiment, a mammalian antibody that binds to ZSCAN5 binds to ZSCAN5A or a variant thereof and / or ZSCAN5B or a variant thereof and / or ZSCAN5C or a variant thereof. In a preferred embodiment, an antibody that binds to ZSCAN5 or a variant thereof binds to ZSCAN5A or a variant thereof, but does not bind to ZSCAN5B or ZSCAN5C. In another preferred embodiment, an antibody that binds to ZSCAN5 or a variant thereof binds to ZSCAN5B or a variant thereof, but does not bind to ZSCAN5A or ZSCAN5C. In another preferred embodiment, an antibody that binds to ZSCAN5 or a variant thereof binds to ZSCAN5C or a variant thereof, but does not bind to ZSCAN5A or ZSCAN5B. In another preferred embodiment, an antibody that binds to ZSCAN5 or a variant thereof binds to all three forms of ZSCAN5 or a variant thereof.

[0040] In a preferred embodiment, the polypeptide comprising at least one epitope of ZSCAN5 comprises the amino acid sequence shown in SEQ ID NO: 8 or a variant thereof.

[0041] In a preferred embodiment, the autoimmune disease is a neurological autoimmune disease, preferably associated with the presence of a mammalian antibody that specifically binds to ZSCAN5 or a variant thereof. In a further preferred embodiment, the autoimmune disease, such as a neurological autoimmune disease, is selected from paraneoplastic neurological syndrome (PNS), dementia, cognitive decline, psychotic symptoms, auditory hallucinations, seizures, encephalitis such as limbic encephalitis or autoimmune encephalitis, epilepsy, neuropsychiatric symptoms, neuromyelitis optica spectrum disorder (neuromyelitis optica Spectrum disorder, NMOSD), neuromyotonia, multiple sclerosis, peripheral polyneuropathy, Guillain-Barré syndrome (Guillain-Barré syndrome, GBS) symptoms, quadriplegia, cerebellar / brainstem syndrome, hearing loss, symmetrical maculopathy, cerebellopontine lesions extending to the spinal cord, personality changes, cognitive disorders and affective disorders, ataxia, such as gait and standing ataxia, neuropathy and multiple cerebral ischemia, preferably selected from PNS, dementia, cognitive decline, encephalitis, such as limbic encephalitis or autoimmune encephalitis, ataxia, such as gait and standing ataxia, neuromyelitis optica spectrum disorder (NMOSD), neuromyotonia, neuropathy, multiple sclerosis, epilepsy and neuropsychiatric symptoms. In another preferred embodiment, the autoimmune disease is associated with cancer, such as carcinoma, brain metastasis, leukemia and melanoma.

[0042] In preferred embodiments, the polypeptide is a recombinant, isolated and / or purified polypeptide.

[0043] In a preferred embodiment, the polypeptide comprising at least one epitope of ZSCAN5 comprises at least one amino acid sequence selected from the group comprising SEQ ID NO: 40, SEQ ID NO: 41 and SEQ ID NO: 42 or a variant thereof. In one embodiment, the polypeptide comprising at least one epitope of ZSCAN5 comprises at least the amino acid sequence as shown in SEQ ID NO: 40 or a variant thereof. In one embodiment, the polypeptide comprising at least one epitope of ZSCAN5 comprises at least the amino acid sequence as shown in SEQ ID NO: 41 or a variant thereof. In one embodiment, the polypeptide comprising at least one epitope of ZSCAN5 comprises at least the amino acid sequence as shown in SEQ ID NO: 42 or a variant thereof.

[0044] In a preferred embodiment, the mammalian antibody is an autoantibody. In one embodiment, the antibody is a human antibody. In one embodiment, the sample is a mammalian sample, preferably a human sample, comprising a group of representative antibodies. In a preferred embodiment, the sample is selected from a group comprising whole blood, plasma, serum, cerebrospinal fluid and saliva. In one embodiment, the sample is a sample previously obtained from a patient. In a preferred embodiment, the mammalian antibody comprises a human Fc region, such as described herein, optionally in combination with a binding region derived from a non-human species. In one embodiment, the mammalian antibody is separated and / or purified. In one embodiment, the mammalian antibody is present in a blood sample, wherein the blood sample is optionally diluted.

[0045] In a preferred embodiment, the mammalian antibody or complex is detected using a detection method selected from immunodiffusion, electrophoresis, light scattering immunoassay, agglutination, labeled immunoassay such as radiolabeled immunoassay, enzyme immunoassay, more preferably ELISA, chemiluminescent immunoassay, preferably electrochemiluminescent immunoassay and immunofluorescence, preferably indirect immunofluorescence.

[0046] In a preferred embodiment, the support is selected from the group consisting of slides, preferably slides for microscopy, biochips, microtiter plates, lateral flow devices, test strips, membranes, preferably line blots, chromatography columns and beads, preferably magnetic beads or fluorescent beads.

[0047] In one embodiment, the method or use of the invention comprises contacting the carrier of the invention with means for detecting mammalian antibodies.

[0048] ZSCAN5 is a transcription factor that occupies the mammalian Pol III promoter and extra TFIIIC (ETC) site. Pol III transcripts are known to be essential for cell survival. ZSCAN5 is represented by ZSCAN5B in mammals, and also includes paralogs ZSCAN5A, ZSCAN5C and ZSCAN5D in higher primates (Sun et al. (2016), Oncotarget 7(45):72571-72592).

[0049] SEQ ID NO: 5 represents the amino acid sequence of ZSCAN5 represented by ZSCAN5A of Homo sapiens. In one embodiment, ZSCAN5 comprises one or more, preferably all, amino acid sequences selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 and / or SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17 and / or SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24 and / or SEQ ID NO: 8 and / or SEQ ID NO: 40.

[0050] SEQ ID NO: 6 represents the amino acid sequence of ZSCAN5 represented by ZSCAN5B of Homo sapiens. In one embodiment, ZSCAN5 comprises one or more, preferably all, amino acid sequences selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 and / or SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20 and / or SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24 and / or SEQ ID NO: 8 and / or SEQ ID NO: 41.

[0051] SEQ ID NO: 7 represents the amino acid sequence of ZSCAN5 represented by ZSCAN5C of Homo sapiens. In one embodiment, ZSCAN5 comprises one or more, preferably all, amino acid sequences selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 and / or SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17 and / or SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20 and / or SEQ ID NO: 8 and / or SEQ ID NO: 42.

[0052] In a preferred embodiment, ZSCAN5 is from a mammal selected from the group consisting of humans, non-human primates, rodents, cows, horses, dogs, cats, bears, donkeys, sheep, goats, camels and dromedaries, more preferably humans.

[0053] In a preferred embodiment, the method or use according to the present invention comprises a step of providing a carrier according to the present invention. At least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof may be immobilized on the solid surface of the carrier, or the tool for capturing antibodies and / or the tool for detecting antibodies may be configured to immobilize at least one polypeptide of the present invention on the carrier, which may be performed at a later stage, but before removing the sample and washing the carrier. If the carrier or polypeptide is not yet immobilized on the carrier, it may then be contacted with a sample suspected of containing antibodies under conditions that allow any antibodies to bind to ZSCAN5. If the polypeptide is not yet immobilized on the carrier, it may be immobilized on the carrier. However, it will be readily understood by those skilled in the art that this may also be done during subsequent steps of the method or use, if desired. Then, the sample may be removed and the carrier or polypeptide may be washed to remove any remaining sample. Then, the tool for detecting antibodies carrying a detectable label, such as a fluorescent dye, may be contacted with the carrier or polypeptide under conditions that allow any bound antibodies and the tool to form a complex. The carrier or polypeptide may be washed again. Finally, the presence of the antibody may be detected by checking whether a tool such as a secondary antibody can be detected. Preferably, ELISA or immunofluorescence assays can be used, which use mammalian cells or tissues expressing polypeptides comprising an antigen of the present invention or a variant thereof. In the case of immunofluorescence, a unique pattern determined by the expression pattern of the antigen in the cell or tissue can indicate the presence of the antibody, as performed or shown in the examples. In the case of ELISA or another semiquantitative or quantitative detection method, a value above a cutoff value determined as known in the art can indicate the presence of the antibody.

[0054] In one embodiment, the methods, uses, antibodies, carriers or kits described herein can be used to provide data, such as data on the presence or absence of antibodies in a sample or liquid, which can, for example, allow a clinician to draw or partially draw conclusions about clinical manifestations, along with other factors. For the avoidance of any doubt, when considered alone, providing data (e.g., on the presence or absence of antibodies to ZSCAN5) does not allow a diagnosis to be reached. However, it can help clinicians direct their efforts in a certain direction to reach a diagnosis.

[0055] Competitive assays, capture bridge assays, immunoassays, class-specific secondary antibodies on solid phases, direct or indirect class capture assays can also be used. The principles of each format are described in detail in The Immunoassay Handbook, 3rd edition, edited by David Wild, Elsevier, 2005. In short, in a competitive format, the antibody to be detected may compete with the recombinant antibody for binding sites on an antigen (e.g., ZSCAN5 or at least one polypeptide comprising at least one epitope of ZSCAN5). Alternatively, a sample containing an antibody can be pre-incubated with an antigen in one reaction, subsequently exposed to an immobilized antigen or an antigen configured for immobilization, and can be exposed to an antigen in another reaction without pre-incubation with the antigen to show specific binding. In a capture bridge assay, two antigen molecules bind to two antigen binding sites on the antibody to be detected. One of the antigen molecules is labeled, and the other is fixed or configured for fixation, preferably by an affinity tag and a ligand that specifically binds to the affinity tag. In an immunoassay, the antibody to be detected binds to an antigen, which can be fixed after or before binding. Antibodies can be detected using tools such as secondary antibodies for detecting antibodies. In direct class capture assays, the antibody to be detected can be immobilized using a tool for capturing the antibody and detected using a labeled antigen. In indirect class capture assays, the antibody to be detected can be immobilized using a tool for capturing the antibody. Detection can be performed using at least one, preferably two, antigen molecules that bind to the antibody to be detected and a tool for detecting the antibody, such as a secondary antibody. The secondary antibody can optionally be labeled.

[0056] In a preferred embodiment, the carrier and the tool for capturing mammalian antibodies and / or the tool for detecting mammalian antibodies are configured to fix the tool on the solid surface of the carrier. In another preferred embodiment, the carrier and the polypeptide of the present invention are configured to fix the polypeptide, and / or fix the polypeptide on a solid such as a carrier. A particularly preferred way to configure or fix is ​​to modify the carrier and / or tool or the carrier and / or polypeptide, respectively, so that they contain affinity tags and ligands of affinity tags. Alternatively, the carrier or tool or polypeptide may contain reactive chemical groups, such as thiol, amino, epoxy, ester and anhydride groups, respectively. In a preferred embodiment, the term "immobilization" as used herein refers to the binding of molecules to solid carriers that are insoluble in aqueous solution, more preferably by covalent or non-covalent bonds, electrostatic interactions, encapsulation, non-specific absorption, printing or embedding, such as by denaturing globular polypeptides in gels, or by hydrophobic interactions, most preferably by one or more covalent bonds. Various suitable supports, such as paper, polystyrene, metal, silicon or glass surfaces, microfluidic channels, membranes, beads such as magnetic beads, column chromatography media, biochips, polyacrylamide gels, etc. have been described in the literature, for example in Kim, D. and Herr, AE (2013), Protein immobilization techniques for microfluidic assays, Biomicrofluidics 7 (4), 041501. In this way, the immobilized molecule together with the insoluble support can be directly separated from the aqueous solution, for example by centrifugation or decantation. The immobilized molecule can be fixed in a reversible or irreversible manner. For example, if the molecule interacts with the support through ionic interactions (which can be masked by adding high concentrations of salt), or if the molecule is bound by a cleavable covalent bond (e.g., a disulfide bridge, which can be cleaved by adding a thiol-containing reagent), the fixation is reversible. In contrast, if the molecule is connected to the carrier by a covalent bond that cannot be cleaved in aqueous solution, such as a bond formed by the reaction of an epoxy group and an amine group (commonly used to couple lysine side chains to affinity columns), the fixation is irreversible. Proteins can be indirectly fixed, such as by fixing antibodies or other entities with affinity for the molecule, followed by forming a complex to achieve the effect of the molecule-antibody complex being fixed. Various methods for fixing molecules are described in the literature, such as in Kim, D. and Herr, AE (2013), Protein immobilization techniques for microfluidic assays, Biomicrofluidics 7 (4), 041501. In addition, various reagents and kits for immobilization reactions are commercially available, such as from Pierce Biotechnology.

[0057] According to the present invention, a cell may be provided, comprising an expression vector comprising a nucleotide sequence encoding at least one polypeptide under the control of a promoter, the polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof, the promoter being optionally a strong promoter and / or an inducible promoter. The vector may encode an N-terminal or C-terminal affinity tag preferably fused to at least one polypeptide via a linker sequence. Cells may be cultured under conditions that allow expression of at least one polypeptide of the present invention. Any expressed polypeptide may then be purified, preferably using an affinity tag. However, in some embodiments, unpurified polypeptides may also be used. Subsequently, it may be fixed to a carrier according to the present invention. In a preferred embodiment, cells, nucleic acids or vectors may be used to manufacture a kit, optionally for use in diagnosing or assisting in the diagnosis of autoimmune diseases, such as neurological autoimmune diseases.

[0058] According to the present invention, the medical or diagnostic device of the present invention, such as a carrier, preferably a diagnostically useful carrier, can be prepared by expressing a recombinant polypeptide comprising a variant of ZSCAN5 or at least one epitope of ZSCAN5 or its variant in a cell, such as a eukaryotic or prokaryotic cell, wherein the recombinant polypeptide comprises an affinity tag, optionally with an artificial linker, which may include a protease cleavage site. Preferably, the polypeptide is contacted with a ligand that specifically binds to the affinity tag, which ligand may be immobilized on a solid phase, the solid phase is washed to remove non-specifically bound material from the cell, and the expressed variant is eluted from the solid phase, preferably by adding an excess of non-immobilized ligand. The variant can then be immobilized on the device. Optionally, the affinity tag can be removed by contacting the variant with a protease, preferably a protease that recognizes the protease cleavage site, before immobilization. The affinity tag can be selected from the group comprising the tag His, immobilized nickel, glutathione, chitin, 18A, ACP, Aldehyd, Avi, BCCP, calmodulin, chitin binding protein, E-tag, ELK16, FLAG, flash, polyglutamic acid, polyaspartic acid, GST, GFP, HA, Isope, maltose binding protein, myc, nus, NE, ProtA, ProtC, Thold4, S-Tag, SnoopTag, SpyTag, SofTag, streptavidin, Strep-tag II, T7 epitope tag, TAP, TC, thioredoxin, Ty, V5, VSV, biotin, Xpress tag and recombinant antibodies bound to the ligand for affinity tags. Useful proteases include but are not limited to TEV, thrombin, Faktor Xa or enteropeptidase. Suitable linkers are part of a vector (e.g., pET vector series (Novagen)).

[0059] In a preferred embodiment, the absence or presence of two or more mammalian antibodies directed against two or more polypeptides each comprising at least one epitope of ZSCAN5 are detected simultaneously (ie, at the same time).

[0060] In another preferred embodiment, the presence or absence of at least one mammalian antibody other than the mammalian antibody that specifically binds to ZSCAN5 is detected, preferably a mammalian antibody that specifically binds to NMDAR, a mammalian antibody that specifically binds to LgI1, a mammalian antibody that specifically binds to AMPA1, a mammalian antibody that specifically binds to AMPA2, a mammalian antibody that specifically binds to CASPR2, a mammalian antibody that specifically binds to GABA B, a mammalian antibody that specifically binds to GABA A, a mammalian antibody that specifically binds to DPPX, a mammalian antibody that specifically binds to IGLON5, a mammalian antibody that specifically binds to Hu, a mammalian antibody that specifically binds to Yo, a mammalian antibody that specifically binds to CRMP5, a mammalian antibody that specifically binds to Ri, a mammalian antibody that specifically binds to Ma2, a mammalian antibody that specifically binds to amphoterin, a mammalian antibody that specifically binds to recovery protein, a mammalian antibody that specifically binds to RGS8, a mammalian antibody that specifically binds to DAGLA, a mammalian antibody that specifically binds to NSF, a mammalian antibody that specifically binds to STX1B, a mammalian antibody that specifically binds to DNM1, a mammalian antibody that specifically binds to VAMP2, a mammalian antibody that specifically binds to Anna-3, a mammalian antibody that specifically binds to Zic-4, Mammalian antibodies that specifically bind to SOX1 (US7314721), mammalian antibodies that specifically bind to PCA2, mammalian antibodies that specifically bind to Tr, mammalian antibodies that specifically bind to glutamate decarboxylase, mammalian antibodies that specifically bind to AK5, mammalian antibodies that specifically bind to AP3B2, mammalian antibodies that specifically bind to raftin 1 / 2, mammalian antibodies that specifically bind to GRM1, mammalian antibodies that specifically bind to GRM2, mammalian antibodies that specifically bind to GRM5, mammalian antibodies that specifically bind to GLURD2, mammalian antibodies that specifically bind to ITPR1, mammalian antibodies that specifically bind to KCNA2, mammalian antibodies that specifically bind to NCDN, mammalian antibodies that specifically bind to septin 3+5+6+7+11, and mammalian antibodies that specifically bind to Sez6L2. In a preferred embodiment, any of these mammalian antibodies is a mammalian autoantibody, preferably a human autoantibody. In a preferred embodiment, detecting the presence of any of these mammalian antibodies helps diagnose an autoimmune disease, such as a neurological autoimmune disease, or suggests the diagnosis thereof. In a preferred embodiment, two or more mammalian antibodies are detected in the same sample, and preferably are detected substantially simultaneously. The carrier according to the invention may be configured to detect two or more mammalian antibodies in the same sample, preferably substantially simultaneously.

[0061] In a preferred embodiment, the presence or absence of two or more mammalian antibodies is detected and distinguishable. In other words, the signal indicating the presence of an antibody indicates which of the two antibodies is present. In a preferred embodiment, the presence or absence of two or more mammalian antibodies is detected in spatially separated reactions, more preferably in different reaction mixtures in separate containers. In another preferred embodiment, the signal indicating the presence of one of the two antibodies can be distinguished from the signal indicating the presence of the other antibody. This can be achieved by using different detectable labels, more preferably distinguishable fluorophores. For example, a fluorophore that emits green light and another fluorophore that emits red light can be used.

[0062] In a preferred embodiment, the presence or absence of two or more mammalian antibodies is detected, but cannot be distinguished. In a preferred embodiment, their presence or absence is detected in a one-pot reaction without spatial separation and without signal distinction, preferably in two or more reactions in the same reaction vessel. In other words, the signal indicates the presence of at least one of the two or more antibodies, but does not indicate which one. In a preferred embodiment, two or more antigens (e.g., represented by two or more polypeptides each comprising at least one epitope of ZSCAN5) can be present in a mixture.

[0063] In a preferred embodiment, the sample comprises a panel of representative antibodies, preferably mammalian antibodies, more preferably IgG, IgA and IgM class antibodies, most preferably IgG class antibodies. It is preferably selected from optionally diluted whole blood, plasma, serum, cerebrospinal fluid (CSF) and saliva. The sample can be a liquid sample or a dried blood spot prepared using a sample, preferably whole blood, plasma, serum or capillary blood, preferably capillary blood.

[0064] In a preferred embodiment, the sample is from an organism having a brain and producing antibodies, preferably from the group comprising mammals and birds, more preferably from a mammal such as a human, non-human primate, rodent (e.g., rat or mouse), cow, horse, dog, cat, bear, donkey, sheep, goat, camel and dromedary, most preferably a human. In another preferred embodiment, it is from a bird, more preferably from the group comprising a chicken, a parrot and a falcon.

[0065] The mammalian antibody to be detected or the means for detecting or capturing the antibody (e.g., mammalian and / or immobilized antibody) specifically binds to its interaction partner, which in the case of a mammalian antibody may be an antigen such as ZSCAN5 or a variant thereof, or in the case of a means for detecting the antibody is an antibody, preferably a mammalian antibody that specifically binds to ZSCAN5 or a variant thereof. In a preferred embodiment, the terms "specifically bind", "specifically bind", "specifically capture" and similar terms used herein refer to a binding reaction ratio with a dissociation constant of 1×10 -5 M, more preferably 1×10 -7 M, more preferably 1×10 -8 M, more preferably 1×10 -9 M, more preferably 1×10 -10 M, more preferably 1×10 -11 M, more preferably 1×10 -12 The binding reaction characterized by M (as measured by surface plasmon resonance using a Biacore instrument at 25° C. in PBS buffer, pH 7) was stronger.

[0066] In a preferred embodiment, the mammalian antibody is a mammalian autoantibody. In a preferred embodiment, the term "autoantibody" as used herein refers to an antibody that specifically binds to a structure, preferably an antigen, such as ZSCAN5, from an organism that produces the antibody, wherein the level of such an antibody is preferably elevated compared to the level in an ordinary healthy subject. Therefore, autoantibodies are endogenous molecules produced in a subject. The organism is preferably a patient suspected of or actually suffering from a disease, preferably a mammal, more preferably a human patient. This autoantibody has a constant region, and other antibodies of the same class from the same organism also have a constant region. Typically, the constant region of a mammalian antibody, such as an autoantibody, can be composed of a heavy chain constant region (C H ) and the light chain constant region (C L ). In one embodiment, the mammalian (auto) antibody comprises a C selected from the group consisting of SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50 and SEQ ID NO: 51 or variants thereof. H , preferably C selected from the group consisting of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 and SEQ ID NO: 50 or variants thereof HIn one embodiment, the mammalian (auto)antibody comprises a C selected from the group consisting of SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56 and SEQ ID NO: 57 or variants thereof. L . Particularly preferably, the autoantibody is a human autoantibody, more preferably a human autoantibody of the IgG, IgM or IgA class, preferably IgG. The variable domain is capable of specifically binding to an antigen, such as ZSCAN5 or a variant thereof. In one embodiment, the constant region specifically binds to a molecule that recognizes the constant region of an antibody, such as an IgG class antibody, such as a secondary antibody. It may have sequence elements common to other antibodies (such as IgG class antibodies) from the same organism. Therefore, the autoantibody may have a sequence from an antibody constant region from an animal (preferably a human), but the variable region is capable of specifically binding to an endogenous molecule of the animal, such as ZSCAN5 or a variant thereof. In a preferred embodiment, the (auto)antibody is separated and / or purified from a sample (preferably tissue, serum, plasma, blood or CSF from an animal (preferably a human). The autoantibody can be isolated from an animal or patient as a mixture of polyclonal natural antibodies. It is not a synthetic, monoclonal or recombinant antibody. Recombinant antibodies that specifically bind to ZSCAN5 or a variant thereof can be produced using standard methods known in the art. It can be used as a positive control and for detection assays, such as sandwich assays or competitive assays.

[0067] According to the present invention, a mammalian antibody that specifically binds to ZSCAN5 or a variant thereof is provided or isolated. Those skilled in the art are familiar with the separation or purification of antibodies. Comprehensive descriptions can be obtained in the prior art, for example in Affinity Chromatography Vol.1 Antibody by GE Healthcare, www.gelifesciences.com, April 2016 and Thermo Scientific Pierce Antibody Production and Purification Technical Handbook, Version 2, www.thermoscientific.com. For example, a specific purification step may involve affinity chromatography using a polypeptide comprising an antigen of the present invention or a variant thereof that is fixed to beads by coupling using primary amines and / or protein G, such as at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof.

[0068] The teachings of the present invention can be carried out not only using polypeptides, in particular at least one polypeptide comprising the native sequence of at least one epitope of ZSCAN5 or nucleic acids having the exact sequence explicitly (e.g. by function, name, sequence or accession number) or implicitly referred to in the present application, but also using variants of such polypeptides or nucleic acids. For the avoidance of doubt, in a preferred embodiment, a polypeptide comprising at least one epitope of ZSCAN5 comprises a polypeptide comprising the complete amino acid sequence of ZSCAN5 or a variant thereof which is not truncated at one or both ends of ZSCAN5. However, in other preferred embodiments, the term also relates to a polypeptide which does not comprise the complete amino acid sequence of ZSCAN5, for example, which comprises the amino acid sequence of ZSCAN5 truncated at one or both ends, as long as it comprises at least one epitope of ZSCAN5, preferably an immunogenic epitope or a variant thereof, as described herein.

[0069] In a preferred embodiment, the term "variant" as used herein may refer to at least one fragment of the full-length sequence involved, more specifically, one or more amino acid or nucleic acid sequences that are truncated at one or both ends relative to the full-length sequence. Such fragments contain or encode at least 6, 7, 8, 9, 10, 12, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 250, 300, 350, 400, 410, 420, 430, 440, 450, 460, 470, 480 or 490 consecutive amino acids having the original sequence or a variant thereof. The total length of the variant can be at least 6, 7, 8, 9, 10, 12, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 250, 300, 350, 400, 410, 420, 430, 440, 450, 460, 470, 480, or 490 amino acids or more.

[0070] The term "variant" refers not only to at least one fragment, but also to a polypeptide or fragment thereof comprising an amino acid sequence that is at least 40, 50, 60, 70, 75, 80, 85, 90, 92, 94, 95, 96, 97, 98, 99, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8 or 99.9, preferably at least 80% or 99% identical to the reference amino acid sequence or fragment thereof, wherein the amino acids other than those necessary for biological activity, such as the ability of an antigen to bind to an antibody, or the folding or structure of the polypeptide, are deleted or substituted and / or one or more such essential amino acids are replaced in a conservative manner and / or amino acids are added, such that the biological activity of the polypeptide is retained. In other words, in a preferred embodiment, the variant retains the biological activity (of the full-length protein from which it is derived). The prior art includes various methods that can be used to align two given nucleic acid or amino acid sequences and calculate the degree of identity, see, for example, Arthur Lesk (2008), Introduction to bioinformatics, Oxford University Press, 2008, 3rd edition. In a preferred embodiment, ClustalW software (Larkin, MA, Blackshields, G., Brown, NP, Chenna, R., McGettigan, PA, McWilliam, H., Valentin, F., Wallace, IM, Wilm, A., Lopez, R., Thompson, JD, Gibson, TJ, Higgins, DG (2007). Clustal W and Clustal X version 2.0. Bioinformatics, 23, 2947-2948) is used with default settings.

[0071] In a preferred embodiment, the polypeptide and variants thereof may comprise a tag, such as an affinity tag, wherein the tag is preferably selected from the group comprising: His tag, GST tag, E tag, FLAG tag, HA tag, myc tag, V5 tag, S tag, SnoopTag, SpyTag, SofTag, Strep tag, Strep tag II, T7 epitope tag, immobilized nickel, glutathione, chitin, 18A, biotin tag, ALFA tag, AviTag, ACP, BCCP, calmodulin, chitin binding protein, ELK16, C-Tag, calmodulin tag, iCap tag, polyglutamic acid tag, polyarginine tag, NE-tag, Rho1D4-tag, SBP-tag, Softag 1, Softag 2. 3. Spot-tag, T7-tag, TC-tag, Ty-tag, VSV-tag, TAP-tag, thioredoxin, flash, polyaspartate, Isope, maltose binding protein, myc, nus, NE, ProtA, ProtC, Tho1d4 and Xpress-tag.

[0072] In a preferred embodiment, the polypeptide and its variants may further comprise chemical modifications, such as isotope labeling, or covalent modifications, such as glycosylation, phosphorylation, acetylation, decarboxylation, citrullination, methylation, hydroxylation, ubiquitination, etc. Those skilled in the art are familiar with methods for modifying polypeptides. Any modification is designed so that it does not eliminate the biological activity of ZSCAN5 or its epitope or a variant of the protein or its epitope.

[0073] In addition, variants can also be produced by fusing the polypeptide, its fragment or variant with the N-terminus or / and C-terminus of other known polypeptides or variants thereof or artificial sequences (e.g., linkers), and contain active parts or domains, preferably having at least 70%, 75%, 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity when compared with the active part of the reference sequence, wherein the term "active part", as used herein, refers to an amino acid sequence that is less than the full-length amino acid sequence, or in the case of a nucleic acid sequence, encodes less than the full-length amino acid sequence, and / or is a variant of the natural sequence, but retains at least some biological activity. Preferably, the active part is an active part of ZSCAN5. The polypeptide may contain additional sequences, preferably artificial sequences, such as linkers or binding epitopes. Any fusion sequence is selected so that the ability of the antigen of the present invention or its variant to specifically bind to the antibody to be detected or the diagnostic reliability (especially sensitivity and / or specificity) is not significantly changed, let alone eliminated.

[0074] In a preferred embodiment, the term "variant" of a nucleic acid includes a nucleic acid whose complementary strand is preferably hybridized to a reference or wild-type nucleic acid under stringent conditions. The stringency of the hybridization reaction can be easily determined by a person of ordinary skill in the art, and is typically an empirical calculation that depends on probe length, washing temperature, and salt concentration. For more detailed information and explanations on the stringency of the hybridization reaction, see Ausubel, FM (1995), Current Protocols in Molecular Biology. John Wiley & Sons, Inc. In addition, those skilled in the art can follow the manual Boehringer Mannheim GmbH (1993) The DIG System Users Guide for Filter Hybridization, Boehringer Mannheim GmbH, Mannheim, Germany, and Liebl, W., Ehrmann, M., Ludwig, W. and Schleifer, KH (1991) International Journal of Systematic Bacteriology 41: 255-260 for instructions on how to identify a DNA sequence by hybridization. In a preferred embodiment, the term variant of a nucleic acid sequence as used herein refers to any nucleic acid sequence that encodes the same amino acid sequence as a reference nucleic acid sequence (preferably at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof) in accordance with the degeneracy of the genetic code.

[0075] In a preferred embodiment, the term "sensitivity" refers to the number of samples correctly determined to be positive relative to the total number of samples examined. In a preferred embodiment, the term "specificity" refers to the number of samples correctly determined to be negative relative to the total number of samples examined.

[0076] Variants of the antigens described herein (e.g., ZSCAN5) or at least one polypeptide comprising at least one epitope of an antigen described herein (e.g., ZSCAN5) have biological activity. In preferred embodiments, such biological activity is the ability to specifically bind to mammalian antibodies that specifically bind to the antigen, e.g., ZSCAN5, such as found in patients with autoimmune diseases (e.g., neurological autoimmune diseases, preferably associated with the presence of such antibodies in the sample). In the case of ZSCAN5, an autoimmune disease, such as a neurological autoimmune disease, is preferably selected from PNS, dementia, cognitive decline, psychotic symptoms, auditory hallucinations, epileptic seizures, encephalitis such as limbic encephalitis or autoimmune encephalitis, epilepsy, neuropsychiatric symptoms, NMOSD, neuromyotonia, neuropathy, multiple sclerosis, peripheral polyneuropathy, Guillain-Barre syndrome (GBS) symptoms, quadriplegia, cerebellar / brainstem syndrome, hearing loss, symmetrical maculopathy, cerebellopontine lesions extending to the spinal cord, personality changes, cognitive disorders and affective disorders, ataxia (e.g., gait and standing ataxia), multiple cerebral ischemia and / or cancer (e.g., cancer, brain metastases and melanoma). In a preferred embodiment, dementia is rapidly progressive dementia. In other preferred embodiments, encephalitis is limbic encephalitis or autoimmune encephalitis, optionally in combination with epilepsy and / or neuropsychiatric symptoms. In a further preferred embodiment, cancer is breast cancer or lung cancer (NSCLC). For example, a variant of the polypeptide can be examined for such biological activity by determining whether the variant of the polypeptide specifically binds to a sample of mammalian antibodies from such patients that contains mammalian antibodies that specifically bind to a wild-type antigen, such as ZSCAN5 (preferably by indirect immunofluorescence assay, such as described in the experimental section of this application). In a preferred embodiment, those skilled in the art will consider that domains exposed to the cytoplasm or extracellular space may contain epitopes of mammalian antibodies to be detected when designing variants.In an even more preferred embodiment, the variant of ZSCAN5 may be a polypeptide comprising at least one sequence selected from the group comprising SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 or variants thereof and / or SEQ ID NO: 8 or variants thereof and / or selected from the group comprising SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17 or variants thereof and / or selected from the group comprising SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20 or variants thereof and / or selected from the group comprising SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24 or variants thereof and / or selected from the group comprising SEQ ID NO: 40, SEQ ID NO: 41 and SEQ ID NO: 42 or variants thereof. In an even more preferred embodiment, the variant is a polypeptide comprising at least SEQ ID NO: 8 or variants thereof. In another even more preferred embodiment, the variant is a polypeptide comprising at least one amino acid sequence selected from the group comprising SEQ ID NO: 40, SEQ ID NO: 41 and SEQ ID NO: 42 or variants thereof.

[0077] Polypeptides for implementing the teachings of the present invention, including any variants, are preferably designed so that they contain at least one epitope that is recognized and / or specifically bound by an antibody that specifically binds to an antigen (e.g., ZSCAN5). The epitope may exhibit the strongest binding to an antibody that binds to an antigen (e.g., ZSCAN5) compared to the binding observed for other antibodies. In one embodiment, such polypeptides comprise 6, 7, 8, 9, 10, 11, 12, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 113, 125 or more, preferably at least 9 but no more than 16 consecutive amino acids from an antigen (e.g., ZSCAN5) as described herein. Those skilled in the art are familiar with guidelines for designing peptides with sufficient immunogenicity, such as those described in Jackson, DC, Fitzmaurice, CJ, Brown, LE, Zeng, W. (1999), Preparation and properties of totally synthetic immunogenes, Vaccine, Vol. 18, No. 3-4, September 1999, pp. 355-361; and Black, M., Trent, A., Tirrell, M. and Olive, C. (2010), Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists, Expert Rev Vaccines, February 2010; 9(2): 157-173. In short, it is desirable that the peptide meets as many of the following requirements as possible: (a) it is highly hydrophilic, (b) it contains one or more residues selected from aspartic acid, proline, tyrosine and phenylalanine, (c) for greater specificity, has no or little homology with other known peptides or polypeptides, (d) it needs to be sufficiently soluble, and (e) it does not contain glycosylation or phosphorylation sites unless they are required for specific reasons. Alternatively, bioinformatics methods such as those described by Moreau, V., Fleury, C., Piquer, D., Nguyen, C., Novali, N., Villard, S., Laune, D., Granier, C. and Molina, F. (2008), PEPOP: Computational design of immunogenic peptides, BMC Bioinformatics 2008, 9: 71 can be followed.

[0078] When used according to the present invention, the polypeptide of the present invention can be provided in any type of conformation. For example, the polypeptide can be a substantially unfolded, partially or completely folded polypeptide. In a preferred embodiment, polypeptide folding means that the epitope or protein or its variant necessary for binding the antibody of the present invention adopts the folding adopted by the native protein in its natural environment in its entirety. Those skilled in the art are familiar with methods suitable for determining whether the polypeptide is folded and if folded, what kind of structure it has, such as limited proteolysis, NMR spectroscopy, CD spectroscopy or X-ray crystallography (see, for example, Banaszak LJ (2008), Foundations of Structural Biology, Academics Press, or Teng Q. (2013), Structural Biology: Practical Applications, Springer), preferably using CD spectroscopy.

[0079] The polypeptide of the present invention may be a fusion protein comprising an amino acid sequence other than the amino acid sequence taken from ZSCAN5, in particular a C-terminal or N-terminal tag, preferably an N-terminal tag, which in a preferred embodiment is another sequence motif or polypeptide having a certain biological or physical function and can be used, for example, for purification, fixation, precipitation or identification of the polypeptide of the present invention. In a more preferred embodiment, the tag is a sequence or domain capable of specifically binding to a ligand, for example, selected from the group comprising His tag, thioredoxin, maltose binding protein, glutathione-S-transferase, fluorescent tags, for example, selected from the group comprising green fluorescent protein.

[0080] According to the present invention, at least one cell is provided, which overexpresses at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof, preferably with at least one polypeptide overexpressed in a polypeptide comprising Hu, Yo, Ri, CV2, PNMA1, PNMA2, DNER / Tr, ARHGAP26, ITPR1 (EP14003703.7), ATP1A3, NBC1 (EP14003958.7), neurochondroitin (EP15001186), CARPVIII, Zic4, SOX1 (US7314721), Ma, MAG, MPO, MBP, GAD65, amphotericin, recovery protein, GABA A receptor, GABA B receptor, glycine receptor, ponsin, IgLON5, DPPX, aquaporin-4, MOG, NMDA receptor, AMPA receptor, GRM1, GRM5, LGI1, VGCC, mGluR1, CASPR2, ATP1A3 (also known as the α3 subunit of human neuronal Na(+) / K(+) ATPase) (EP14171561.5) and raftin 1 / 2 (EP3101424) or another antigen thereof or a variant thereof.

[0081] In preferred embodiments, the term "overexpression" as used herein refers to cells that have been transfected with a nucleic acid comprising a nucleic acid sequence encoding at least one polypeptide under the control of a promoter, the polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof, or other antigens or variants thereof as described herein. Thus, the transfected cells typically express more polypeptides recognized by the mammalian antibody to be specifically bound to to be detected than cells of the same type, which may be at least 10%, 20%, 30%, 50%, 100%, 200% or 500% more, as judged by quantitative protein blotting. The promoter may be an inducible promoter, which allows expression to be induced by the addition of an inducer. Those skilled in the art are familiar with protocols and vectors for transient overexpression of polypeptides in eukaryotic cells, such as the pTriEx system from Novagen, and protocols and vectors for stable transfection of eukaryotic cells, such as the pcDNA from Invitrogen. TM 4 / TO carrier system.

[0082] In a preferred embodiment, fixed mammalian cells can be used. In a preferred embodiment, the term "fixed" cells used herein refer to cells that have been treated with a reactive chemical compound, the effect of which is that the cell is no longer metabolically active, but still presents its epitope for immunostaining using antibodies and subsequent detection (e.g., by fluorescence). More preferably, the reactive compound is selected from the group comprising acetone, formalin, methanol and ethanol or a mixture thereof, preferably all of them. Those skilled in the art are familiar with protocols that can be used to prepare fixed cells.

[0083] In one embodiment, the cell can be located on a carrier for micro-immunofluorescence analysis, which can also include simulated transfected cells that can be used as a negative control. This carrier can be a glass slide. The cells on a carrier such as a glass slide can be covered with a mounting buffer. Mounting buffer is a liquid that helps maintain a pH value close to physiology to maintain the molecular structure of any diagnosis-related molecule and its epitope, is compatible with the emission of fluorescent signals, and prevents premature loss of fluorescence due to fluorophore bleaching. It can be selected from water, glycerol, natural oils or plastics or mixtures thereof, preferably water and glycerol. Various compositions are described in the prior art, for example in "Mountants and Antifades", Wright Cell Imaging Facility, Toronto Western Research Institute University Health Network, (https: / / de.scribd.com / document / 47879592 / Mountants-Antifades), Krenek et al. (1989) J. Immunol. Meth 117, 91-97 and Nairn et al. (1969) Clin. Exp. Immunol. 4, 697-705. Preparation and evaluation of cells using microscopy are well known in the art and are described, for example, in "IIFT: Neurology Mosaics Instructions for use", FA_112d-1_A_UK_C17.doc, V.04 / 05 / 2022 from EUROIMMUN Medizinische Labordiagnostika, AG.

[0084] In a preferred embodiment, the cell is a eukaryotic cell overexpressing the polypeptide, for example a cell selected from the group comprising HEK, Hela, CHO and Jurkat cells and derivatives thereof. In a preferred embodiment, the cell is a recombinant cell overexpressing the polypeptide, preferably under the control of a strong heterologous promoter.

[0085] In another preferred embodiment, the carrier, for example, a diagnostically useful carrier, is a bead. Various beads for a variety of applications are commercially available, mainly based on carbohydrates, such as sepharose or agarose, or plastics. They can contain active or activatable chemical groups, such as carboxyl or tosyl or ester groups, which can be used to fix tools for specific capture antibodies. Preferably, beads are beads with an average diameter of 0.1 μm to 10 μm, 0.5 μm to 8 μm, 0.75 μm to 7 μm or 1 μm to 6 μm. Preferably, beads are provided in the form of an aqueous suspension, and their bead content is 10 to 90%, preferably 20 to 80%, preferably 30 to 70%, more preferably 40 to 60% (w / w). The person skilled in the art is familiar with such beads (Diamindis, EP, Chriopoulus, TK, Immunoassays, 1996, Academic Press), which are commercially available, for example Bio-Plex COOH beads MC10026-01 or 171-506011 from Bio-Rad.

[0086] In another preferred embodiment, the carrier is a microtiter plate comprising a plurality of wells, such as at least 8 wells, that can be used for ELISA. At least one well is coated with a means for direct or indirect specific capture of an antibody, preferably at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof. At least 3, preferably 4, more preferably 5 or even more calibrants of a specified concentration can be used to establish a calibration curve for semi-quantitative analysis. When implementing the method of the present invention, calibrants that generally cover the concentration range covering the calibration curve can be processed and developed in parallel with the sample. A secondary antibody comprising a detectable label, such as an enzyme activity label, can be provided, such as a label with horseradish peroxidase activity or alkaline phosphatase activity or an enzyme capable of chemiluminescence.

[0087] In another preferred embodiment, the carrier is a microarray. In a preferred embodiment, the term "microarray" as used herein refers to a chip with multiple spatially separated antigens, preferably at least 5, more preferably 10, 20, 30, 40, 50, 80 or 100 or even more. Preferably, each antigen is a peptide comprising or consisting of 5 to 25, preferably 7 to 16 consecutive amino acids across mammalian protein fragments. At least one antigen is a polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof. Preferably, two or more antigens are polypeptides each comprising at least one epitope of ZSCAN5 or a variant thereof, as described herein. A secondary antibody comprising a label, preferably a fluorescent label and specifically binding to anti-human IgG can be used for detection. Preferably, at least one additional antigen or variant thereof is spotted.

[0088] In a preferred embodiment, ELISA is used to determine the presence of mammalian antibodies that bind to an antigen described herein, such as ZSCAN5, in a sample from a subject. In another preferred embodiment, immunofluorescence, preferably indirect immunofluorescence, is used to determine the presence of mammalian antibodies that bind to an antigen described herein, such as ZSCAN5, in a sample from a subject.

[0089] According to the present invention, a tool for detecting an antibody is used, which is a molecule that specifically binds to an antibody and allows detection, and generally comprises a detectable label. In one embodiment, the tool for detecting an antibody is a second antibody or a polypeptide comprising at least one epitope of an antigen such as ZSCAN5, wherein the tool is combined with the antibody to be detected. In a preferred embodiment, a detectable label can be used to distinguish a molecule population from other molecule populations using a biophysical detection method. It is preferably selected from a group including fluorescence, radioactivity, chemiluminescent labeling, heavy metals such as gold labels, nanoparticles, beads or enzyme activity labels, preferably a label that catalyzes a colorimetric reaction. In a preferred embodiment, a fluorescent label is selected from a group comprising Alexa dyes, FITC, TRITC and green fluorescent protein (GFP). Iodine-125 can be used as a radioactive label. In a preferred embodiment, an enzyme activity label is selected from a group comprising horseradish peroxidase, glucose oxidase, beta galactosidase, alkaline phosphatase and luciferase. In a preferred embodiment, a chemiluminescent label is selected from a group comprising luminol or a derivative, acridinium ester and luciferase. Those skilled in the art are able to select appropriate labels and attach them to proteins, nucleic acids and other molecules (Hassanzadeh L, Chen S, Veedu RN. Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging. Pharmaceuticals (Basel). 2018; 11 (4): 106. Published on October 15, 2018. doi: 10.3390 / ph11040106Hassanzadeh L, Chen S, Veedu RN. Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging. Pharmaceuticals (Basel). 2018; 11 (4): 106. Published on October 15, 2018. doi: 10.3390 / ph11040106, Bioconjugate Techniques, 3rd edition (2013), Greg T. Hermanson, Obermaier C, Griebel A, Westermeier R. Principles of protein labeling techniques. Methods Mol Biol. 2015; 1295: 153-65), and a variety of labeled molecules are commercially available.According to the invention, the means for capturing antibodies, such as IgG class antibodies, are molecules that specifically bind to the antibody to be immobilized and are able to immobilize it, because it is itself immobilized or configured to be immobilized, preferably by an affinity tag. In one embodiment, the means for detecting the immobilized antibody can be selected from the group comprising a secondary antibody that binds to a mammalian antibody (e.g., a secondary antibody that binds to IgG, preferably IgG1 and / or IgA and / or IgM), a polypeptide comprising ZSCAN5 or a variant thereof, a polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof, a ligand that specifically binds to ZSCAN5, protein G or a variant thereof, or an aptamer or antibody that specifically binds to the immobilized antibody.

[0090] According to the present invention, the term "secondary antibody" in its broadest sense is to be understood as referring to any kind of "binding moiety" capable of specifically binding to antibodies of the IgA, IgG and / or IgM class or fragments thereof (e.g., constant regions of a specific Ig class of a selected species, preferably a human species), preferably a binding protein, such as described herein. Non-limiting examples of binding moieties include antibodies, such as antibodies immunologically or genetically derived from any species, such as humans, chickens, camels, llamas, lampreys, sharks, goats, rodents, cows, dogs, rabbits, etc., antibody fragments, domains or parts thereof, such as Fab, Fab', F(ab')2, scFab, Fv, scFv, VH, VHH, VL, VLR, etc., diabodies, monoclonal antibodies (mAb), polyclonal antibodies (pAb), mAbdAbs, phage display derived binders, affibodies, heterologous conjugate antibodies, bispecific antibodies, evibodies, lipocalins, anticalins, affibodies , avimers, maxibodies, heat shock proteins (e.g., GroEL and GroES), translocons, DARPins, aptamers, C-type lectin domains such as tetranectins; human γ-crystallin and human ubiquitin-derived binders, such as affilins, PDZ domain-derived binders; scorpion toxin and / or Kunitz-type domain binders, fibronectin-derived binders such as adnectins, receptors, ligands, lectins, streptavidin, biotin, including derivatives and / or combinations thereof, such as bi / multispecific formats formed by two or more of these binding molecules.Various antibody-derived and alternative (i.e., non-antibody) binding protein scaffolds, including methods for their generation, are known in the art (e.g., Chiu ML et al., Antibodies (Basel), (2019); 8(4):55; Simeon R. & Chen Z., Protein Cell. (2018); 9(1):3-14; and Chapter 7 - Non-Antibody Scaffolds from Handbook of Therapeutic Antibodies (2007), Stefan Dübel ed., US 7,166,697, Rothe C & Skerra A., BioDrugs. (2018); 32(3):233-243; Gebauer M & Skerra A, Curr Opin Biotechnol. (2019); 60:230-241; Feldwisch, J & Tolmachev, V. (2012) Methods Mol.Biol.899:103-126; Wikman M et al., Protein Eng Des Sel. (2004); 17(5):455-62; Silverman J et al. (2005), Nat Biotechnol 23:1556-1561; Plückthun A., Annu Rev Pharmacol Toxicol. (2015); 55:489-511; Hosse RJ et al. (2006). Protein Sci 15:14-27; Hackel BJ, et al. (2008) J Mol Biol 381:1238-1252). In a preferred embodiment, the secondary antibody is an antibody that binds to all antibodies from the antibody or immunoglobulin class, preferably the human antibody class, preferably IgA and / or IgG and / or IgM antibodies, more preferably IgG. The second antibody can recognize the constant region of the class (e.g., described herein) or one or more epitopes of a sequence or 3D structure common to antibodies across the Ig class of interest. The second antibody is usually from a mammal other than a human or from a bird, preferably from a chicken, rabbit, mouse, rat, horse, pig, donkey, goat, cattle, camel, llama or non-human primate. The second antibody can be a monoclonal antibody, preferably a recombinant antibody, or can be a polyclonal antibody. Many of them are commercially available. In a preferred embodiment, the second antibody specifically binds to human IgG, more preferably to the constant region of human IgG, and even more preferably to an amino acid sequence selected from the group comprising SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 and SEQ ID NO: 50 or its variants.

[0091] In a preferred embodiment, as used herein, the ligand of the affinity tag is an artificial entity that specifically binds to the affinity tag, typically a chemically synthesized modification or a recombinant protein or peptide attached to a molecule of interest. The ligand of the affinity tag depends on the type of affinity tag selected and can be selected from His, immobilized nickel, glutathione, chitin, 18A, ACP, Aldehyd, Avi, BCCP, calmodulin, chitin binding protein, E-tag, ELK16, FLAG, flash, polyglutamic acid, polyaspartic acid, GST, GFP, HA, Isope, maltose binding protein, myc, nus, NE, ProtA, ProtC, Tho1d4, S-Tag, SnoopTag, SpyTag, SofTag, streptavidin, Strep-tag II, T7 epitope tag, TAP, TC, thioredoxin, Ty, V5, VSV, biotin, Xpress tag, and a recombinant antibody that binds to the ligand for the affinity tag.

[0092] According to the present invention, a mammalian antibody that specifically binds to ZSCAN5 is provided, preferably in a liquid, the liquid comprising one or more, more preferably all, selected from the group comprising artificial buffers, preservatives and artificial anticoagulants and / or selected from the group comprising blood, such as whole blood, plasma, serum and CSF. Artificial buffers are synthetic and / or buffers that may not be present in the patient's body or are present at a concentration that is at least much lower than the concentration used. The buffer may be selected from Tris, phosphate, Tricine, acetate, MOPS, MES, carbonate, citrate and HEPES. In a preferred embodiment, the term "preservative" as used herein refers to a substance that inhibits microbial growth and / or chemical degradation in a liquid solution, and may preferably be selected from azide, lactic acid, nitrate, nitrite, antibiotics, protease inhibitors and ethanol.

[0093] The various methods or uses according to the invention can be performed with samples from subjects or patients as described herein. These methods or uses can also be characterized as "in vitro" methods or "in vitro" uses.

[0094] In a preferred embodiment, the term "chemical solution reacted with a detectable label" refers to a compound in a liquid that emits a detectable signal when exposed to a detectable label. The solution may include a chromogenic substrate for an enzyme activity label. For example, if the label is a peroxidase, 3,3',5,5'tetramethylbenzidine / H2O2 may be used. The solution may include a small inorganic or organic compound that can react with a chemiluminescent label. In the case of acridinium esters, a mixture of H2O2 and sodium hydroxide is generally used as a chemical solution. Various other chemical solutions and detectable labels are known in the art (Weeks, I., Beheshti, I., McCapra, F., Campbell, AK, Woodhead, JS (1983) Acridinium esters as high specific activity labels in immunoassay. Clin Chem 29: 1474-1479), ThermoScientific Pierce Antibody Production and Purification Technical Handbook, Version 2, www.thermoscientific.com).

[0095] In preferred embodiments, the methods, uses, mammalian antibodies, carriers and kits described herein are used to diagnose diseases and / or to assist in the diagnosis of diseases. In preferred embodiments, the term "diagnosis" as used herein should be understood in its broadest possible sense, and may refer to any type of procedure intended to obtain information that helps to assess whether a patient (whether a known or anonymous subject from a cohort) has or may have or is more likely to have a disease or condition than an average subject or a comparison subject (the latter preferably has similar symptoms) in the past, at the time of diagnosis, or in the future, to find out how the disease progresses or may progress in the future or to assess the overall responsiveness of one or more patients to a treatment (e.g., administration of an immunosuppressive drug), or to find out whether a sample is from such a patient. Such information can be used for clinical diagnosis, but can also be obtained by an experimental and / or research laboratory for the purpose of general research, such as to determine the proportion of subjects with the disease in a patient cohort or population. In other words, the term "diagnosis" includes not only diagnosis, but also prediction and / or monitoring of the course of a disease or condition, including monitoring the response of one or more patients to the administration of a drug or candidate drug, such as to determine its efficacy. While the results can be assigned to a specific patient for clinical diagnostic applications and can be communicated to a physician or institution treating the patient, this is not necessarily the case for other applications, such as in diagnostics for research purposes, where it may be sufficient to assign the results to a sample from an anonymous patient. Thus, in some embodiments, the person to be diagnosed, i.e., a "subject" or "patient," is an anonymous blood donor whose blood may be donated or used to obtain therapeutically or diagnostically useful antibodies. The term "diagnosis" also refers to a negative diagnosis, i.e., a situation where no mammalian antibodies that specifically bind to ZSCAN5 are found in a sample from a patient. In these embodiments, the absence of mammalian antibodies that specifically bind to ZSCAN5 indicates that the patient may have a disease other than the disease associated with the presence of the antibody, as described herein. In a preferred embodiment, the disease associated with the presence of antibodies that specifically bind to ZSCAN5 is an autoimmune disease, such as a neurological autoimmune disease, as described herein. Thus, in one embodiment, "diagnosis" also includes situations where the absence of mammalian antibodies that specifically bind to ZSCAN5 helps to exclude certain diseases, such as diseases associated with the presence of such antibodies, as described herein, which may lead to an indirect diagnosis of another disease. In another preferred embodiment, detection of mammalian antibodies that specifically bind to ZSCAN5 is considered to mean that the neurological autoimmune disease is definitively diagnosed due to the presence of the antibodies.

[0096] Thus, in preferred embodiments, the terms "diagnosis", "diagnosing" or "diagnostic" or similar terms encompass the diagnosis, prognosis, therapeutic diagnosis and monitoring of autoimmune diseases, preferably neurological autoimmune diseases (such as those described herein) and / or cancer (such as those described herein). As used herein, the term "theranostic" refers to identifying, for example by diagnostic methods, patients who may benefit from a particular therapy and, optionally, subsequent treatment of the patient.

[0097] In preferred embodiments, the methods and products according to the invention can be used for interaction studies, including determining whether a candidate drug or other compound can interfere with the binding of a mammalian antibody that specifically binds to ZSCAN5 or can affect any downstream processes or the strength of its binding to its target. In preferred embodiments, they can be used to monitor immune responses, more preferably the appearance and / or titer of antibodies against ZSCAN5, after administration (e.g., to a mammal, which can be a mammal other than a human, such as an experimental animal) of an immunogenic composition containing at least one polypeptide comprising at least one epitope of ZSCAN5 or an immunogenic variant thereof.

[0098] In preferred embodiments, the methods and products can be used to provide reagents, such as mammalian antibodies to ZSCAN5, which can be used as positive controls or calibrators for diagnostic or analytical tests, or for developing and / or validating diagnostic or analytical tests. In preferred embodiments, the term "validation" as used herein refers to a procedure for establishing an assay in a specific setting based on previously known principles and confirming that it produces useful results. For example, although the present application discloses the usefulness of mammalian antibodies to ZSCAN5 as markers for diagnosis or auxiliary diagnosis, a clinical or research laboratory may need to confirm the diagnostic value of the results before routinely using the test for its patients or a new group of patients, such as a group of animals (who may not have been previously known to have a disease or condition).

[0099] In another preferred embodiment, the methods and products according to the present invention can be used to determine the concentration of antibodies that specifically bind to ZSCAN5. In a more preferred embodiment, the antibody is a mammalian antibody from a patient with an autoimmune disease, such as a neurological autoimmune disease. In another preferred embodiment, the antibody is a recombinant antibody that binds to ZSCAN5 but is recognized by a secondary antibody that specifically binds to human IgG class antibodies, preferably IgG1, IgG2, IgG3 and IgG4 isotypes. In a more preferred embodiment, it is necessary to determine such a concentration for research purposes, for preparation or for monitoring the quality of reagents, animal models or devices that may or may not be used to diagnose neurological autoimmune diseases or to assist in such diagnosis.

[0100] In many cases, only detecting mammalian antibodies (in other words, determining whether there is a detectable level of antibody in a sample) is sufficient for diagnosis. In a preferred embodiment, this may involve determining whether the concentration is at least 10% higher than the concentration of the antibody of interest found in a normal healthy subject, preferably 20%, 50%, 100%, 200%, 500%, 1,000%, 2,000%, 2,500%, 5,000%, 10,000%, 20,000%, 50,000%, 100,000%, 1,000,000% or 10,000,000%, preferably, wherein the antibody is not detectable in a normal healthy subject. If the antibody can be detected, this will provide useful information for the clinician's diagnosis. This may indicate the increased likelihood that the patient suffers from a certain disease.

[0101] Those skilled in the art will understand that clinicians usually do not draw conclusions on whether a patient suffers from or may suffer from a disease, condition or illness based solely on a single diagnostic parameter, but need to take into account other aspects, such as the presence of other antibodies, markers, blood parameters, clinical evaluation of patient symptoms or the results of medical imaging or other non-invasive methods (such as polysomnography) to draw a conclusive diagnosis. Referring to Baenkler HW (2012), General aspects of autoimmune diagnostics, in Renz, H., Autoimmune diagnostics, 2012, de Gruyter, page 3. The value of a diagnostic agent or method may also be to exclude the possibility of a disease, thereby allowing indirect diagnosis of another disease. In a preferred embodiment, the meaning of any symptom or disease mentioned throughout the application meets the understanding of those skilled in the art as of the application date or preferably the earliest priority date of the application as demonstrated by textbooks and scientific publications. In a preferred embodiment, the method or purposes or product is not used alone to reach a clear and final diagnosis.

[0102] In a preferred embodiment, any information or data demonstrating the presence or absence of the antibody can be communicated to the patient or the physician treating the patient verbally, preferably by telephone, in written form, preferably by fax or letter, or in electronic form by fax or the Internet such as e-mail or text message.

[0103] The teachings of the present invention, such as the methods, uses, antibodies, carriers and kits described herein, may also be used in a method for preventing or treating a disease, preferably after diagnosis according to the present invention, comprising the steps of a) reducing the concentration of mammalian antibodies binding to ZSCAN5 in the blood of the subject and / or b) administering one or more immunosuppressive drug substances, preferably selected from rituximab, prednisone, methylprednisolone, cyclophosphamide, mycophenolate mofetil, intravenous immunoglobulin, tacrolimus, cyclosporine, methotrexate and azathioprine.

[0104] According to the present invention, the presence of antibody can be determined in a qualitative or quantitative manner. In a preferred embodiment, the term "detecting in a quantitative manner" used herein refers to not only detecting the presence of antibody, but also obtaining the result of information including the absolute or relative amount of antibody in the sample. In a more preferred embodiment, the value representing the absolute concentration is obtained. In another more preferred embodiment, the value representing the relative concentration or concentration change is obtained. In another preferred embodiment, also referred to as a "semi-quantitative" method, the concentration of the antibody is placed in one of several groups, most preferably, meaning a concentration window in which it does not actually exist, meaning a concentration window in which a boundary result is obtained, and meaning a concentration window of the presence of the antibody. Can be further distinguished into categories such as "weakly positive" or "strongly positive" signals.

[0105] As used herein, the term "isolated" means that the molecule referred to as isolated is free or substantially free of at least one component found in nature. For example, a molecule, such as a mammalian antibody, may be free or substantially free of some or all components as found in its natural environment. For example, in the case of a mammalian antibody, such components may include red blood cells, white blood cells, platelets, plasma, proteins, nucleic acids, salts, lipids, and nutrients.

[0106] The method according to the invention is preferably an in vitro method.

[0107] According to the present invention, polypeptides, such as at least one polypeptide comprising at least one epitope of ZSCAN5 or its variants, may be recombinant polypeptides. In preferred embodiments, the term "recombinant" as used herein refers to polypeptides produced using genetic engineering methods at any stage of the production process, such as by fusing a nucleic acid encoding the polypeptide with a strong promoter to overexpress in a cell or tissue or by engineering the sequence of the polypeptide itself. Those skilled in the art are familiar with engineered nucleic acids and encoded polypeptides (e.g., described in Sambrook, J., Fritsch, EF and Maniatis, T. (1989), Molecular Cloning, CSH or Brown TA (1986), Gene Cloning-an introduction, Chapman & Hall) and methods for producing and purifying natural or recombinant polypeptides (e.g., manuals published by GE Healthcare Life Sciences "Strategies for Protein Purification", "Antibody Purification" and Burgess, RR, Deutscher, MP (2009): Guide to Protein Purification). In other preferred embodiments, the polypeptide provided or used according to the present invention, such as a polypeptide or antibody comprising at least one epitope of ZSCAN5 or a variant thereof, is an isolated polypeptide, wherein the term "isolated" may mean that the polypeptide is enriched compared to the state when produced using biotechnology or synthetic methods, and is preferably pure, i.e. at least 60%, 70%, 80%, 90%, 95% or 99% of the polypeptide in the corresponding liquid consists of the polypeptide, as judged by SDS polyacrylamide gel electrophoresis, followed by Coomassie blue staining and visual inspection. Preferably, any polypeptide on the carrier is pure.

[0108] Patients with mammalian antibodies against ZSCAN5 may suffer from a variety of cancers, including breast cancer, lung cancer (NSCLC), brain metastases, and melanoma. In preferred embodiments, the term "cancer" as used herein refers to a group of diseases involving abnormal cell growth and the potential to invade or spread to other parts of the body.

[0109] In preferred embodiments, the terms "breast cancer" or "breast cancer" are used interchangeably herein and are defined as cancers that originate from the breast, and the cells have a malignant form and structure, the ability to grow uncontrolled, and the potential or ability to invade or metastasize. In preferred embodiments, breast cancer can spread to other organs, such as lymph nodes. In further preferred embodiments, breast cancer is invasive and can be metastatic.

[0110] In preferred embodiments, the term "non-small cell lung cancer (NSCLC)" as used herein includes epidermoid carcinoma cells, adenocarcinoma cells and large cell undifferentiated carcinoma cells. The most common symptoms associated with NSCLC are cough (including hemoptysis), weight loss, shortness of breath and chest pain.

[0111] In preferred embodiments, the term "brain metastasis" as used herein refers to a tumor that originates outside the central nervous system (CNS, such as the brain and spinal cord) and spreads thereto via the bloodstream or invades directly from adjacent tissues. Metastatic tumors are the most common tumors affecting the brain and spinal cord.

[0112] In preferred embodiments, the term "melanoma" as used herein refers to a malignant tumor of melanocytes. Melanocytes are cells that produce melanin, which is responsible for the color of the skin. They occur primarily in the skin, but also in other parts of the body, including the intestines and eyes. Melanoma can occur anywhere in the body that contains melanocytes.

[0113] Additional background and definitions related to cancer and its diagnosis or differential diagnosis (including antibody detection) can be taken from neurology textbooks available as of the earliest priority date or filing date of this application, such as Kaye, Textbook of Medical Oncology, 3rd edition, Taylor & Francis; Shoenfeld, Meroni and Gershwin, Autoantibodies 3rd edition, Elsevier, particularly Part 11, including Chapter 76; and Darnell and Posner, Paraneoplastic Syndromes, Oxford University Press, 2011.

[0114] Patients with antibodies to ZSCAN5 or its variants may suffer from a variety of neurological autoimmune diseases, including PNS, dementia, cognitive decline, psychotic symptoms, auditory hallucinations, neuropsychiatric symptoms, seizures, epilepsy, encephalitis such as limbic encephalitis or autoimmune encephalitis, neuromyelitis optica spectrum disorder (NMOSD), neuromyotonia, neuropathy, multiple sclerosis, peripheral polyneuropathy, Guillain-Barré syndrome (GBS) symptoms, quadriplegia, cerebellar / brainstem syndrome, hearing loss, Symmetrical maculopathy, cerebellopontine lesions extending to the spinal cord, personality changes, cognitive and affective disorders, ataxias such as gait and stance ataxias, multiple cerebral ischemias and cancers such as carcinomas, brain metastases, leukemias and melanomas, preferably PNS, dementia, cognitive decline, encephalitis such as limbic encephalitis or autoimmune encephalitis, neuromyelitis optica spectrum disorder (NMOSD), neuromyotonia, neuropathy, multiple sclerosis, ataxias (e.g. gait and stance ataxias), epilepsy and neuropsychiatric symptoms.

[0115] In preferred embodiments, the term "ataxia" as used herein refers to a lack of voluntary coordination of muscle movements, which may include gait abnormalities, speech changes, and eye movement abnormalities. Ataxia is a clinical manifestation indicating dysfunction of the part of the nervous system that coordinates movement, such as the cerebellum.

[0116] In preferred embodiments, the term "polyneuropathy" as used herein refers to diseases that affect peripheral nerves in approximately the same area on both sides of the body (peripheral neuropathy) and are characterized by weakness, numbness, and burning pain.

[0117] In preferred embodiments, the term "encephalitis" as used herein refers to inflammation of the brain, symptoms of which include decreased or altered consciousness, personality changes, psychotic delusions, rigidity, headache, fever, confusion, stiff neck, and vomiting. Complications may include seizures, hallucinations, difficulty speaking, memory problems, and hearing problems. The disease may be the result of an infection or may be an autoimmune disease, and therefore detection of antibodies according to the invention may be used to distinguish between these two types of encephalitis.

[0118] In preferred embodiments, the term "neuropsychiatric symptoms" as used herein refers broadly to non-cognitive disorders, including depression, psychosis, agitation, aggression, apathy, sleep disturbances and disinhibition. Neuropsychiatric symptoms are known to accompany cognitive decline, such as dementia, and are present in almost all cases of dementia.

[0119] In preferred embodiments, the term "dementia" as used herein refers broadly to any illness, disease or syndrome characterized by abnormally high and progressive loss of brain function capacity. The signs of dementia include impairment of several core psychological functions, including memory, communication and language, the ability to concentrate, reasoning and judgment, and visual perception. Dementia patients may have problems with short-term memory impairment, not remembering handbags or wallets, paying bills, planning and preparing meals, remembering appointments or going out for travel. Dementia may be progressive, which means that symptoms begin slowly and gradually worsen. Dementia can be determined using standard clinical procedures, and the degree of dementia is defined by the score in the Mini Mental State Examine (MMSE), as described in detail in Folstein MF, Folstein SE and McHugh PR, J Psychiatry Res., 12: 189-198 (1975).

[0120] In preferred embodiments, the term "ischemia" as used herein refers to a condition caused by a reduction or lack of blood flow and oxygen to a part of the body, such as the brain, heart, or other tissues. Ischemic injury generally refers to damage to a distal tissue or tissue damage otherwise caused by loss of blood flow and oxygen. Ischemic injury is generally caused by a lack of oxygen and fluid, but also includes inflammatory cascades. For example, ischemia and ischemic injury can occur due to heart, lung or brain injury, organ transplantation or surgery, or disease or condition (e.g., sickle cell anemia or sickle cell disease). In a more preferred embodiment, the ischemia is multiple cerebral ischemia.

[0121] In preferred embodiments, the term "paraneoplastic neurological syndrome" (PNS) as used herein refers to a neurological syndrome associated with the presence of a cancer associated with a tumor that presents antigens that are typically unique to the nervous system. As a result, antibodies are produced that specifically bind to neural antigens, which may damage the nervous system. Manifestations of PNS include, but are not limited to, encephalitis (often associated with epileptic seizures), psychiatric manifestations (e.g., hallucinations, anxiety, and depression), cerebellar symptoms (e.g., ataxia, nystagmus, and dysarthria), opsoclonus-myoclonus, and sensory neuronopathy; and Lambert-Eaton myasthenic syndrome. It should be mentioned that PNS-associated tumors are usually small, grow slowly, and may not be detectable when neurological symptoms appear. The PNS can be bound to one or more antibodies that can specifically bind to autoantigens from the group consisting of NMDAR, LgI1, AMPA1, AMPA2, CASPR2, GABA B, GABA A, DPPX, IGLON5, Hu, Yo, CRMP5, Ri, Ma2, amphoterin, recoverin, RGS8, DAGLA, NSF, STX1B, DNM1 and VAMP2, Hu, Ri, Ma, Anna-3, Zic-4, SOX1, Yo, PCA2, Tr and glutamate decarboxylase.

[0122] Additional background and definitions related to neurological syndromes and symptoms and their diagnosis or differential diagnosis (including detection of antibodies) can be taken from neurology textbooks available on the earliest priority date or filing date of this application, such as Simon, Greenberg, Aminoff, Clinical Neurology, 7th edition, 2009, McGraw; Shoenfeld, Meroni and Gershwin, Autoantibodies 3rd edition, Elsevier, particularly Part 11, including Chapter 76; and Darnell and Posner, Paraneoplastic Syndromes, Oxford University Press, 2011.

[0123] The methods described herein for determining the presence of mammalian antibodies that bind to ZSCAN5 in a sample can be combined with methods for determining the presence of other antibodies, the presence of which is associated with the occurrence of a disease or a similar disease as described herein. For example, at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof as described herein can be used in combination with one or more polypeptides or variants thereof that bind to other antibodies, the presence of which is associated with the occurrence of a disease or a similar disease as described herein. For example, a device containing at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof, such as a device of the present invention, can contain other polypeptides or variants thereof that bind to other antibodies, the presence of which is associated with the occurrence of a disease or a similar disease as described herein. Such devices can be used to analyze the presence of any antibodies in a sample from a subject (e.g., a patient), the presence of which is associated with the occurrence of a disease or a similar disease as described herein. In the case of a method using such an apparatus or using multiple apparatuses, each apparatus containing at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof, or a polypeptide that binds to another antibody that does not bind to ZSCAN5, the presence of which is associated with the occurrence of a disease described herein or a similar disease, determining the presence of any antibody that binds to any of the polypeptides or variants thereof determined may be sufficient for the skilled person to draw a conclusion about the presence of certain diseases or to limit suspected diseases to certain diseases or to assist in the diagnosis of diseases, as described herein, or to obtain information about the subject's risk of having or developing a disease described herein in the present, past or future. Thus, in some cases, determining the presence of an antibody that binds to ZSCAN5 or any other antibody that does not bind to ZSCAN5 (but whose presence is associated with the occurrence of a disease described herein or a similar disease) may be sufficient without obtaining information or drawing a conclusion about which specific antibody is present in a given sample, as long as the presence of the antibody is associated with the occurrence of the same or a similar disease. Thus, determining the presence of a mammalian antibody that binds to ZSCAN5 may include determining the presence of any antibody, the presence of which is associated with the occurrence of a disease described herein or a similar disease associated with the presence of a mammalian antibody to ZSCAN5.

[0124] Those skilled in the art will appreciate that in some cases, it may be helpful to first analyze the clinical symptoms of a patient suffering from or suspected of suffering from a disease associated with or suspected of being associated with the presence of antibodies that bind to ZSCAN5. Depending on the symptoms, the extent of the injury, and other factors known in the art, the clinician or another medical or scientific personnel may then determine whether the antibody titer of the subject to be analyzed is increased compared to a healthy subject or compared to the antibody titer of the subject being analyzed before the onset of symptoms or compared to the average level. Subsequently or independently, one or more methods as described herein may be performed, such as for determining the presence of mammalian antibodies that bind to ZSCAN5, to determine the presence of such antibodies and / or to determine the presence of any antibodies, the presence of which is associated with a disease described herein. Therefore, determining the presence of mammalian antibodies that bind to ZSCAN5 can be used as a preliminary investigation or as an investigation in addition to others, thereby allowing the clinician to conclude whether the subject is currently, in the past, or in the future suffering from or may suffer from a disease. Determining the presence of mammalian antibodies that bind to ZSCAN5 can also be used to distinguish between drug or alcohol use or abuse or the presence of an infectious disease, or the presence of a psychiatric disease that is not autoimmune in nature, and the presence of an autoimmune disease, as described herein.

[0125] In certain embodiments, it may be helpful to determine the Ig class of antibodies that bind to ZSCAN5. Thus, in one embodiment, determining the presence of mammalian antibodies that bind to ZSCAN5 comprises determining the Ig class of the antibodies. In other embodiments, determining the presence of mammalian antibodies that bind to ZSCAN5 does not include determining the Ig class of the antibodies. Similarly, determining the presence of a certain Ig class of mammalian antibodies that bind to ZSCAN5 may include determining the presence of other Ig classes of antibodies that bind to ZSCAN5. Determining the presence of a certain Ig class of mammalian antibodies that bind to ZSCAN5 may also include determining the absence of the antibodies, for example, by obtaining a negative result, which may indicate that antibodies that bind to ZSCAN5 are not present in the sample being assayed.

[0126] As part of the diagnosis of a neurological syndrome associated with antibodies that specifically bind to ZSCAN5, clinicians will first consider a series of tests and risk factors that may point them to an autoimmune disease or infectious disease for many conditions associated with the presence of mammalian antibodies that specifically bind to ZSCAN5 (Lancaster, J Clin Neurol. 2016 Jan; 12 (1) https: / / doi.org / 10.3988 / jcn.2016.12.1.1, Lee and Lee, The Laboratory Diagnosis of Autoimmune Encephalitis, Journal of Epilepsy Research 6 (2), 45), preferably encephalitis, more preferably limbic encephalitis or autoimmune encephalitis, NMOSD, PNS, dementia, multiple sclerosis. Detection of mammalian antibodies that specifically bind to ZSCAN5 will confirm the autoimmune background, while the absence of mammalian antibodies to ZSCAN5 will prompt the clinician to consider autoimmune diseases associated with other antibodies. However, a series of antibodies will usually be tested for presence or absence, and a negative result will indicate an infectious disease. In one embodiment, a negative result may also be interpreted as an indication of alcohol or drug abuse or the presence of a psychiatric condition that is not autoimmune in nature.

[0127] According to the present invention, a kit is provided, comprising cells or carriers, and further comprising one or more, preferably all reagents selected from a second antibody preferably labeled with a detectable marker, a washing solution, a positive control, a negative control, a detergent, a coverslip, a mounting medium, and a physiological saline solution, preferably PBS, or a salt required for preparing it. In a preferred embodiment, the positive control is a diluted sample from a patient with a neurological autoimmune disease, preferably whole blood, more preferably serum or CSF, or a monoclonal or polyclonal antibody that specifically binds to ZSCAN5. The negative control can be a diluted sample from a healthy subject such as a blood donor. The kit may include instructions for how to perform the assay. Preferably, the second antibody is a second antibody that specifically binds to the constant region of an IgG class antibody, preferably a human IgG class antibody, and more preferably a human IgG class antibody. In other preferred embodiments, the second antibody may be labeled (as described above).

[0128] In a preferred embodiment, the present invention provides the use of cells, polypeptides, carriers or mammalian antibodies in preparing a kit or composition (optionally for diagnosis or auxiliary diagnosis of a disease).

[0129] In a preferred embodiment, any method or use according to the invention may be intended for non-diagnostic use, i.e., determining the presence of mammalian antibodies that specifically bind to ZSCAN5, for use other than diagnosing a patient. For example, the method or use may be used to test in vitro the efficiency of a medical device designed to remove mammalian antibodies from a patient's blood, wherein the test is performed on a fluid other than the patient's blood. After the medical device is used on a patient, its ability to remove mammalian antibodies may be checked by passing a solution containing antibodies that specifically bind to ZSCAN5 through the device, and then using a method according to the invention to confirm that there are less or no antibodies in the solution that passes through the device, i.e., indicating that the device still has the ability to remove antibodies from the solution.

[0130] According to the present invention, the method or use can be used to test the efficacy of a candidate drug that can be used to treat a patient suffering from or at risk of suffering from a neurological autoimmune disease. Such a candidate drug can be any molecule that is capable of interfering with the interaction between ZSCAN5 or a variant thereof and a corresponding mammalian antibody.

[0131] In another preferred embodiment, the method can be used to confirm the reliability of a diagnostic assay (e.g. for diagnosing a disease associated with the presence of mammalian antibodies that bind to ZSCAN5 or a variant thereof) and can involve detecting antibodies that specifically bind to ZSCAN5 in a solution that is not a sample from a patient in need of diagnosis, but is known to contain (preferably at a known concentration) antibodies that specifically bind to ZSCAN5. For example, it can be a recombinant antibody or a sample from an anonymous patient whose identity cannot be traced diluted in a dilution buffer (e.g. PBS). Alternatively, the solution can be a negative control that does not contain specifically binding antibodies to check the background. This method can be run in parallel, after or before the diagnostic method. In a preferred embodiment, any method or use according to the invention can be intended to generate an autoantibody profile, preferably for detecting a disease in a mammal, preferably a human.

[0132] In a preferred embodiment, any method or use according to the invention may be used to identify a subject at risk of having or developing a disease (eg, an autoimmune disease described herein) and / or a cancer (eg, a cancer described herein).

[0133] In a preferred embodiment, the method can be used to detect mammalian antibodies that specifically bind to ZSCAN5 in a solution that is not a sample from a mammal to be diagnosed or for the purpose of providing a diagnosis. In a preferred embodiment, the problem of the present invention is solved by a method comprising the steps of contacting a device comprising a solid phase, on which at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof is immobilized, with a buffer solution, the buffer solution comprising mammalian antibodies that specifically bind to ZSCAN5, the solution preferably not being a sample from a patient to be diagnosed, wherein preferably

[0134] a) the concentration of the antibody in the solution is known, and / or

[0135] b) the antibody is a recombinant antibody and / or

[0136] c) contacting the medical or diagnostic device with two or more solutions comprising the antibody, wherein the two or more solutions have different concentrations of the antibody, and / or

[0137] d) the antibody is recognized by a secondary antibody that specifically binds to IgG antibodies,

[0138] A signal indicating whether the antibody has bound to the polypeptide is then detected, optionally a signal that is correlated with the concentration of the antibody in one or more solutions.

[0139] In a preferred embodiment, the invention provides an apparatus for analyzing a sample from a patient to detect mammalian antibodies against ZSCAN5 (indicative of a neurological autoimmune disease or an increased likelihood of developing the disease), the apparatus comprising:

[0140] a. a carrier comprising means for capturing antibodies from a sample when the sample is contacted with the carrier, preferably wherein the means is a cell or at least one polypeptide and the carrier is a carrier according to the invention,

[0141] b. when the detectable means is contacted with the carrier, a detectable means capable of binding to the antibody captured by the carrier, wherein the detectable means is preferably a labeled secondary antibody capable of binding to the antibody captured on the carrier,

[0142] c. Optionally, means for removing any sample from the support and the detectable means (preferably by washing);

[0143] d. a detection device for detecting the presence of a detectable means and converting the result into an electrical signal, such as a fluorescence reader or a fluorescence microscope, connected to software capable of recognizing a pattern characteristic of stained cells overexpressing a polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof in an image of cells captured by the fluorescence reader or camera, and

[0144] Optionally, means for receiving the electronic signal from the detection device and determining whether the signal level indicates an increased likelihood of having or developing a disease by comparison to a pattern characteristic of wild-type or unstained cells (preferably by mock-transfected cells or cells that are not positively stained with an antibody that specifically binds ZSCAN5 on the same vector), or an input reference value obtained with a sample from a healthy subject, or by comparing the signal level obtained using one sample with the signal level obtained using a second sample obtained at a later time point, preferably at least one month later.

[0145] According to the present invention, a device for removing mammalian antibodies that specifically bind to ZSCAN5 from the blood, preferably serum, of a patient suffering from a neurological autoimmune disease is provided as an in vitro method for removing mammalian antibodies that specifically bind to ZSCAN5 from a patient, wherein the device comprises a carrier having a solid phase on which at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof is immobilized. A device having at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof or a secondary antibody or protein that captures all IgG class antibodies (including IgG class antibodies against ZSCAN5) immobilized thereon can be used. Suitable methods are described in Eisei Noiri and Noria Hanafusa, The Concise Manual of Apharesis Therapy, Springer Tokyo, 2014. Hamilton, P., Kanigicherla, D., Hanumapura, P., Walz, L., Kramer, D., Fischer, M., Brenchley, P. and Mitra, S. (2018) J. Clin. Aph. 33(3), 283-290. Another method is disclosed in EP3477300.

[0146] The term "at least one" includes "exactly one" and "more than one". For example, a polypeptide comprising at least one epitope may refer to a polypeptide comprising only one epitope, but may also refer to a polypeptide comprising more than one epitope (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, or even more epitopes). In some embodiments, the term "one or more" includes "at least one". In some embodiments, "one or more" and "at least one" are interchangeable.

[0147] In some embodiments, the term "preferably" includes "optionally." In some embodiments, "preferably" and "optionally" are interchangeable.

[0148] The present invention is further illustrated by the following non-limiting examples, from which further features, embodiments, aspects and advantages of the present invention can be derived. BRIEF DESCRIPTION OF THE DRAWINGS

[0149] Figure 1 .Immunofluorescence staining of neuronal tissue.

[0150] Cryosections of rat hippocampus and cerebellum and primate cerebellum were incubated with patient sera 1, 2, 3 and 4 (1:32 dilution, green) in the first step and with Alexa488-labeled goat anti-human IgG in the second step. Punctate staining of the granular layer of the primate cerebellum and granular staining of the molecular layer were observed, but no reaction was observed with rat neuronal tissue. sm: molecular layer, sg: granular layer, sp: stratum purkinjense, scale bar 100 μm.

[0151] Figure 2 .Epitope characterization.

[0152] PhIP-Seq analysis showed that the index sample bound to peptides in ZSCAN5B, ZSCAN5C (patient sera 1-4), and ZSCAN5A (patient sera 1 and 3 only), indicating that the epitope must be located between AS272-360 of ZSCAN5B and AS271-360 of ZSCAN5C and ZSCAN5A.

[0153] Figure 3 . Neutralization of antibody responses on neuronal tissue.

[0154] Patient serum 2 (1:32, green) was pre-incubated with extracts of HEK293 cells transfected with an empty control vector or a plasmid containing ZSCAN5B cDNA (1:2) in the first step and with Alexa488-labeled goat anti-human IgG in the second step. Extracts containing ZSCAN5B greatly abolished the immunoreactivity of the serum on monkey cerebellar sections. Nuclei were counterstained by incubation with TO-PRO-3 iodide (blue). Scale bar: 100 μm.

[0155] Figure 4 . Validation of ZSCAN5 as a novel autoantigen by indirect immunofluorescence using recombinant antigens.

[0156] Indirect immunofluorescence assay was performed using acetone-fixed HEK293 cells transfected with patient serum 4 (1:100 dilution) or healthy control (1:10 dilution) and incubated with anti-human IgG-FITC in a second step. Scale bar 100 μm.

[0157] Figure 5 . Validation of ZSCAN5 as a novel autoantigen by Western blotting using recombinant antigens.

[0158] A) Immunoblotting using recombinantly expressed ZSCAN5B-His purified from E. coli incubated with anti-His antibody, sera from 13 patients (PS, one representative blot is depicted) or sera from 15 healthy controls (HC, one representative blot is depicted) (1:200). B) Immunoblotting using epitope-containing fragments of ZSCAN5 expressed in a cell-free protein expression system incubated with sera from four patients (PS, one representative blot is depicted for each ZSCAN paralog).

[0159] sequence

[0160] The present invention comprises a series of novel nucleic acid and amino acid sequences, more specifically

[0161] SEQ ID NO: 1 (fragment of ZSCAN5)

[0162] ESDPIQALRKLTELLCHLWLRPDLHTKEQILDMLVMEQFMI SMPQELQVLV

[0163] SEQ ID NO: 2 (fragment of ZSCAN5)

[0164] NGVQSCKDLEDLLRNNRRPKKWS

[0165] SEQ ID NO: 3 (fragment of ZSCAN5)

[0166] ASVENVDADTPSACVVEREA

[0167] SEQ ID NO: 4 (fragment of ZSCAN5)

[0168] SISQEEPQGEATPVGNRESPGQA

[0169] SEQ ID NO: 5 (ZSCAN5A)

[0170] MAANCTSSWSLGESCNRPGLELPRSMASSETQLGNHDVDPEISHVNFRMFSCPKESDPIQALRKLTELCHLWLRPDLHTKEQILDMLVMEQFMISMPQELQVLVMMNGVQSCKDLEDLLRNNRRPKKWSVVTFHGKEYIVQDSDIEMAEAPSSVRDDLKDVSSQRASSV NQMRPGEGQAHRELQILPRVPALSRRQGEDFLLHKSIDVTGDPKSLRPKQTLEKDLKENREENPGLTSPEPQLPKSPTDLVRAKEGKDPPKIASVENVDADTPSACVVEREASTHSGNRGDALNLSSPKRSKPDASSISQEEPQGEATPVGNRESPGQAGMNSIHSPGPASPVSHPDGQEAKALPPFACDVCEKRFTCNSKLVIHKRSHTGERLFQCNLCGKRFMQLISLQFHQRTHTGERPYTCDVCQKQFTQKSYLKCHKRSHTGEKPFECKDCKKVFTYRGSLKEHQRIHSGEKPYKCSKCPRAFSRLKLLRRHQKTHPEATSQ

[0171] SEQ ID NO:6(ZSACN5B)

[0172] MAANWTLSWGQGGPCNSPGSDTPRSVASPETQLGNHDRNPETWHMNFRMFSCPEESDPIQALRKLTELCHLWLRPDLHTKEQILDMLVMEQFMISMPQELQVLVKVNGVQSCKDLEDLLRNNRRPKKWSIVNLLGKEYLMLNSDVEMAEAPASVRDDPRDVSSQWASSVNQMHPGTGQARREQQILPRVAALSRRQGEDFLLHKSIDVTGDPNSPRPKQTLEKDLKENREENPGLSSPEPQLPKSPNLVRAKEGKEPQKRASVENVDADTPSACVVEREALTHSGNRGDALNLSSPKRSKPDASSISQEEPQGEATPVGNRESPGQAEINPVHSPGPAGPVSHPDGQEAKALPPFACDVCNKSFKYFSQLSIHRRSHTGDRPFQCDLCRKRFLQPSDLRVHQRVHTGERPYMCDVCQKRFAHESTLQGHKRIHTGERPFKCKYCSKVFSHKGNLNVHQRTHSGEKPYKCPTCQKAFRQLGTFKRHLKTHRETTSQ

[0173] SEQ ID NO:7(ZSCAN5C)

[0174] MAANCTSSWSLGESCNPGSEPPQSMPSPATQLGNHDSDPETCHVNFRMFSCPKESDPIQALRKLTELCHLWLRPDLHTKEQILDMLVMEQFMISMPQELQVLVMMNGVQSCKDLEDLLRNNRRPKKWSVVSFLGKEYLMQESDVEMAEA PASVRDDDPRHVSSQRTSSVNQMCPEEGQASQELQTLPRVPALFRRQEEDFLLPETTVMKGDPKALRPKPTLEKDLEEDREENPGLTSPEPQLPNSPTGVVGAKEGKEPQKRASVENVDADTPSACVVEREASTHSGSRGDALNLRGLKRS KPDATSISQEEPQGEATPVGNRESPGQAEINPVHSPGPAGPVSHPSGQEVKELLPFACEVCGKRFKYRGKLAVHTRSHTGERLFQCNLCGKRFMQRIGLQFHQRTHTGERPYTCDICQKQFTQKSYLKCHKRSHTGEKPFECKDCKKVFTYKANLKEHQRIHSGEKPHKCSKCPRAFGRPATLRRHQKTHREATSQ

[0175] SEQ ID NO: 8 (ZSCAN5 epitope)

[0176] X1=T or does not exist

[0177] X2=P or does not exist

[0178] X12=S or L

[0179] X17=S or N

[0180] X25=S or R

[0181] X26=S or G

[0182] X27=P or L

[0183] X35=S or T

[0184] X59=G or E

[0185] X60=M or I

[0186] X62=S or P

[0187] X63=I or V

[0188] X70=S or G

[0189] X76=D or S

[0190] X80=A or V

[0191] X82=A or E

[0192] X84=P or L

[0193] X89=D or E

[0194] X91=C or does not exist

[0195] XXSACVVEREAXTHSGXRGDALNLXXXKRSKPDAXSISQEEPQGEATPVGNRESPGQAXXNXXHSPGPAXPVSHPXGQEXKXLXPFACXVX

[0196] SEQ ID NO: 9 (ZSCAN5 fragment)

[0197] MAANCTSSWSLGESCN

[0198] SEQ ID NO: 10 (ZSCAN5 fragment)

[0199] HVNFRMFSCPKESDPIQALRKLTELCHLWLRPDLHTKEQILDMLVMEQFMISMPQELQVLVMMNGVQSCKDLEDLLRNNRRPKKWSVV

[0200] SEQ ID NO: 11 (ZSCAN5 fragment)

[0201] REENPGLTSPEPQLP

[0202] SEQ ID NO: 12 (ZSCAN5 fragment)

[0203] ASVENVDADTPSACVVEREASTHSG

[0204] SEQ ID NO: 13 (ZSCAN5 fragment)

[0205] RSHTGERLFQCNLCGKRFMQ

[0206] SEQ ID NO: 14 (ZSCAN5 fragment)

[0207] LQFHQRTHTGERPYTCD

[0208] SEQ ID NO: 15 (ZSCAN5 fragment)

[0209] CQKQFTQKSYLKCHKRSHTGEKPFECKDCKKVFTY

[0210] SEQ ID NO: 16 (ZSCAN5 fragment)

[0211] LKEHQRIHSGEKP

[0212] SEQ ID NO: 17 (ZSCAN5 fragment)

[0213] KCSKCPRAF

[0214] SEQ ID NO: 18 (ZSCAN5 fragment)

[0215] SDVEMAEAPASVRDDPR

[0216] SEQ ID NO: 19 (ZSCAN5 fragment)

[0217] AKEGKEPQKRASVENVDADTPSACVVEREA

[0218] SEQ ID NO: 20 (ZSCAN5 fragment)

[0219] SISQEEPQGEATPVGNRESPGQAEINPVHSPGPAGPVSHP

[0220] SEQ ID NO: 21 (ZSCAN5 fragment)

[0221] ALSRRQGEDFLLHKSIDVTGDP

[0222] SEQ ID NO: 22 (ZSCAN5 fragment)

[0223] RPKQTLEKDLKENREENPGL

[0224] SEQ ID NO: 23 (ZSCAN5 fragment)

[0225] THSGNRGDALNLSSPKRSKPDASSISQEEPQGEATPVGNRES PGQA

[0226] SEQ ID NO: 24 (ZSCAN5 fragment)

[0227] PVSHPDGQEAKALPPFACDVC

[0228] SEQ ID NO: 25 (ZSCAN5B, gene synthesis fragment 1, encoding aa1-242)

[0229] ATACGTCTCACATGGCTGCAAATTGGACACTCTCATGGGGTCAGGGAGGACCCTGCAACAGCCCTGGGTCAGACACTCCACGGTCTGTGGCGTCCCCAGAAACTCAACTTGGAAATCACGACAGGAACCCTGAGACTTGGCACATGAATTTCAGGATGTTCAGCTGCCCAGAGGAGTCGGACCCCATCCAGGCTCTGAGGAAACTCACTGAGCTGTGCCATCTGTGGCTGAGGCCCGACCTCCACACCAAAGAGCAGATCCTGGACATGCTGGTGATGGAGCAGTTCATGATCTCCATGCCCCAGGAGCTCCAGGTCTTAGTCAAGGTGAACGGTGTGCAGAGCTGCAAAGACCTGGAGGACCTGCTACGAAATAACAGAAGACCCAAGAAATGGTCTATAGTCAACTTGCTCGGCAAAGAATATCTTATGCTGAACTCAGATGTCGAGATGGCTGAAGCCCCCGCCAGTGTCAGAGATGATCCGAGAGATGTGTCCAGCCAGTGGGCCTCCTCTGTGAACCAGATGCATCCGGGGACAGGCCAGGCCCGCCGAGAGCAGCAGATCCTGCCCAGGGTCGCTGCACTGTCCAGGAGGCAGGGAGAGGACTTTCTGCTACACAAGAGTATTGACGTAACAGGTGACCCAAACTCTCCGAGACCCAAGCAGACCTTGGAGAAGGATCTGAAGGAAAACAGGGAAGAGAACCCAGGACTGTCATCCCCAGAGCCTCAGCTTAGAGACGTAT

[0230] SEQ ID NO: 26 (ZSCAN5B, gene synthesis fragment 2, encoding aa243 - 495)

[0231] TCACGTCTCAGCTTCCAAAGAGTCCCAATCTGGTGAGAGCAAAGGAGGGGAAGGAACCCCAGAAAAGAGCCTCTGTGGAAAATGTGGATGCTGACACACCTTCTGCCTGCGTTGTGGAGAGA GAAGCTTTGACTCACAGCGGGAACAGAGGAGATGCTCTGAATCTGAGCAGTCCCAAAAGAAGCAAACCAGATGCCTCCTCCATTTCCCAAGAAGAGCCTCAAGGAGAAGCCACACCTGTGGGCAACAGAGAATCCCCAGGACAAGCTGAGATCAATCCAGTTCATTCCCCAGGCCCTGCGGGCCCGGTCAGTCACCCAGATGGCCAAGAAGCCAAGGCCCTGCCGCCCTTTGCATGTGACGTGTGCAATAAATCATTTAAGTATTTTTCCCAGCTAAGCATCCACAGGAGGTCACACACAGGAGACAGACCCTTTCAATGTGATCTCTGTCGGAAGCGCTTCTTGCAGCCCTCAGACCTCCGAGTTCACCAGCGAGTCCACACTGGCGAGAGGCCCTACATGTGTGACGTCTGCCAAAAGCGGTTCGCCCACGAGTCCACCTTACAGGGCCACAAGAGGATCCACACCGGGGAGAGGCCGTTTAAATGTAAATACTGCAGCAAAGTTTTCAGCCACAAGGGGAACCTGAACGTTCACCAGCGCACCCACTCCGGAGAGAAGCCCTACAAATGTCCCACCTGTCAAAAGGCCTTCCGTCAGCTGGGGACATTCAAGCGTCACCTGAAAACACACCGGGAAACCACCTCCCAGTGATAATCGACGAGACGCAT

[0232] SEQ ID NO:27 (Sense ZSCAN5B-F3)

[0233] ATACGTCTCACATGGCTGCAAATTGGACACTC

[0234] SEQ ID NO:28 (Antisense ZSCAN5B-F3)

[0235] ATACGTCTCATCGAGCTGGGAGGTGGTTTCCCGGTGTGT TTTC

[0236] SEQ ID NO:29 (ZSCAN5B - PCR - fragment - 3, without stop codon)

[0237] TCACGTCTCAGCTTCCAAAGAGTCCCAATCTGGTGAGAGCAAAGGAGGGGAAGGAACCCCAGAAAAGAGCCTCTGTGGAAAATGTGGATGCTGACACACCTTCTGCCTGCGTTGTGGAGAGAGAAGCTTTGACTCACAGCGGGAACAGAGGAGATGCTCTGAATCTGAGCAGTCCCAAAAGAAGCAAACCAGATGCCTCCTCCATTTCCCAAGAAGAGCCTCAAGGAGAAGCCACACCTGTGGGCA ACAGAGAATCCCCAGGACAAGCTGAGATCAATCCAGTTCATTCCCCAGGCCCTGCGGGCCCGGTCAGTCACCCAGATGGCCAAGAAGCCAAGGCCCTGCCGCCCTTTGCATGTGACGTGTGCAATAAATCATTTAAGTATTTTTCCCAGCTAAGCATCCACAGGAGGTCACACACAGGAGACAGACCCTTTCAATGTGATCTCTGTCGGAAGCGCTTCTTGCAGCCCTCAGACCTCCGAGTTCACCAGCGAGTCCACACTGGCGAGAGGCCCTACATGTGTGACGTCTGCCAAAAGCGGTTCGCCCACGAGTCCACCTTACAGGGCCACAAGAGGATCCACACCGGGGAGAGGCCGTTTAAATGTAAATACTGCAGCAAAGTTTTCAGCCACAAGGGGAACCTGAACGTTCACCAGCGCACCCACTCCGGAGAGAAGCCCTACAAATGTCCCACCTGTCAAAAGGCCTTCCGTCAGCTGGGGACATTCAAGCGTCACCTGAAAACACACCGGGAAACCACCTCCCAGCTCGATGAGACGTATSEQ ID NO:30 (pTriEx - 1 - ZSCAN5B [human])

[0238]

[0239] SEQ ID NO:31 (ZSCAN5B [Human])

[0240] MAANWTLSWGQGGPCNSPGSDTPRSVASPETQLGNHDRNPETWHMNFRMFSCPEESDPIQALRKLTELCHLWLRPDLHTKEQILDMLVMEQFMISMPQELQVLVKVNGVQSCKDLEDLLRNNRRPKKWSIVNLLGKEYLMLNSDVEMAEAPASVRDDPRDVSSQWASSVNQMHPGTGQARREQQILPRVAALSRRQGEDFLLHKSIDVTGDPNSPRPKQTLEKDLKENREENPGLSSPEPQLPKSPNLVRAKEGKEPQKRASVENVDADTPSACVVEREALTHSGNRGDALNLSSPKRSKPDASSISQEEPQGEATPVGNRESPGQAEINPVHSPGPAGPVSHPDGQEAKALPPFACDVCNKSFKYFSQLSIHRRSHTGDRPFQCDLCRKRFLQPSDLRVHQRVHTGERPYMCDVCQKRFAHESTLQGHKRIHTGERPFKCKYCSKVFSHKGNLNVHQRTHSGEKPYKCPTCQKAFRQLGTFKRHLKTHRETTSQ

[0241] SEQ ID NO:32 (pTriEx-1-ZSCAN5B [Human]-His)

[0242]

[0243] SEQ ID NO:33 (VGLUT2[Human]-H8)

[0244] MAANWTLSWGQGGPCNSPGSDTPRSVASPETQLGNHDRNPETWHMNFRMFSCPEESDPIQALRKLTELCHLWLRPDLHTKEQILDMLVMEQFMISMPQELQVLVKVNGVQSCKDLEDLLRNNRRPKKWSIVNLLGKEYLMLNSDVEMAEAPASVRDDPRDVSSQWASSVNQMHPGTGQARREQQILPRVAALSRRQGEDFLLHKSIDVTGDPNSPRPKQTLEKDLKENREENPGLSSPEPQLPKSPNLVRAKEGKEPQKRASVENVDADTPSACVVEREALTHSGNRGDALNLSSPKRSKPDASSISQEEPQGEATPVGNRESPGQAEINPVHSPGPAGPVSHP DGQEAKALPPFACDVCNKSFKYFSQLSIHRRSHTGDRPFQCDLCRKRFLQPSDLRVHQRVHTGERPYMCDVCQKRFAHESTLQGHKRIHTGERPFKCKYCSKVFSHKGNLNVHQRTHSGEKPYKCPTCQKAFRQLGTFKRHLKTHRETTSQLEHHHHHHHH

[0245] SEQ ID NO:34 (GamS-ZSCAN5A-6His)

[0246] MGNAYYIQDRLEAQSWARHYQQLAREEKEAELADDMEKGLPQHLFESLCIDHLQRHGASKKSITRAFDDDVEFQERMAEHIRYMVETIAHHQVDIDSEVGGSGTPSACVVEREASTHSGSRGDALNLRGLKRSKPDATSISQEEPQGEATPVGNRESPGQAEINPVHSPGPAGPVSHPSGQEVKELLPFACEVGGSGHHHHHH

[0247] SEQ ID NO:35 (GamS-ZSCAN5B-6His)

[0248] MGNAYYIQDRLEAQSWARHYQQLAREEKEAELADDMEKGLPQHLFESLCIDHLQRHGASKKSITRAFDDDVEFQERMAEHIRYMVETIAHHQVDIDSEVGGSGSACVVEREALTHSGNRGDALNLSSPKRSKPDASSISQEEPQGEATPVGNRESPGQAEINPVHSPGPAGPVSHPDGQEAKALPPFACDVGGSGHHHHHH

[0249] SEQ ID NO:36 (GamS-ZSCAN5C-6His)

[0250] MGNAYYIQDRLEAQSWARHYQQLAREEKEAELADDMEKGLPQHLFESLCIDHLQRHGASKKSITRAFDDDVEFQERMAEHIRYMVETIAHHQVDIDSEVGGSGTPSACVVEREASTHSGNRGDALNLSSPKRSKPDASSISQEEPQGEATPVGNRESPGQAGMNSIHSPGPASPVSHPDGQEAKALPPFACDVGGSGHHHHHH

[0251] SEQ ID NO:37 (GamS-ZSCAN5A-6His gene fragment, with linker)

[0252] GAGGTGACGGGCCTCAAAGCCGCGTGGGAGTGAGCTAACACCGTGCGTGTTGACAATTTTACCTCTGGCGGTGATAATGGTTGCAGCTACTAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGGAAACGCTTATTACATTCAGGATCGTCTTGAGGCTCAGAGCTGGGCGCGTCACTACCAGCAGCTCGCCCGTGAAGAGAAAGAGGCAGAACTGGCAGACGACATGGAAAAAGGCCTGC

[0253] CCCAGCACCTGTTTGAATCGCTATGCATCGATCATTTGCAAC

[0254] GCCACGGGGCCAGCAAAAAATCCATTACCCGTGCGTTTGATG

[0255] ACGATGTTGAGTTTCAGGAGCGCATGGCAGAACACATCCGG

[0256] TACATGGTTGAAACCATTGCTCACCACCAGGTTGATATTGAT

[0257] TCAGAGGTAGGTGGTAGCGGTACTCCGAGCGCATGTGTGGT

[0258] GGAACGAGAAGCATCGACACATTCAGGGAGCAGAGGGGACG

[0259] CCCTGAATTTACGTGGCCTCAAACGTTCCAAACCCGATGCTA

[0260] CTTCTATTAGCCAAGAGGAACCGCAAGGAGAGGCAACACCG

[0261] GTAGGCAACCGTGAATCTCCTGGCCAGGCAGAGATCAACCC

[0262] TGTTCACTCCCCTGGTCCCGCTGGTCCGGTTTCTCATCCGAG

[0263] CGGGCAGGAGGTCAAAGAACTTCTTCCATTTGCGTGTGAAGT

[0264] AGGTGGTAGCGGTCATCATCACCATCATCATTAAAATGCAAA

[0265] GCCCGCCGAAAGGCGGGCTTTTCTGTACTTCGCAACGATTTC

[0266] GGAGTCCGGAGACTCGCTGTTTTCGAAATTTGCGCTCAAGGG

[0267] CGGGTATTGAACC,843,CAATCCGCCCTCACTACAACCGGAGG

[0268] TGACGGGCCTCAAAGCCGCGTGGGAGTGAGCTAACACCGTG

[0269] CGTGTTGACAATTTTACCTCTGGCGGTGATAATGGTTGCAGC

[0270] TACTAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATG

[0271] GGAAACGCTTATTACATTCAGGATCGTCTTGAGGCTCAGAGC

[0272] TGGGCGCGTCACTACCAGCAGCTCGCCCGTGAAGAGAAAGA

[0273] GGCAGAACTGGCAGACGACATGGAAAAAGGCCTGCCCCAGC

[0274] ACCTGTTTGAATCGCTATGCATCGATCATTTGCAACGCCACG

[0275] GGGCCAGCAAAAAATCCATTACCCGTGCGTTTGATGACGATG

[0276] TTGAGTTTCAGGAGCGCATGGCAGAACACATCCGGTACATG

[0277] GTTGAAACCATTGCTCACCACCAGGTTGATATTGATTCAGAG

[0278] GTAGGTGGTAGCGGTACTCCGAGCGCATGTGTGGTGGAACG

[0279] AGAAGCATCGACACATTCAGGGAGCAGAGGGGACGCCCTGA

[0280] ATTTACGTGGCCTCAAACGTTCCAAACCCGATGCTACTTCTA

[0281] TTAGCCAAGAGGAACCGCAAGGAGAGGCAACACCGGTAGGC

[0282] AACCGTGAATCTCCTGGCCAGGCAGAGATCAACCCTGTTCAC

[0283] TCCCCTGGTCCCGCTGGTCCGGTTTCTCATCCGAGCGGGCAG

[0284] GAGGTCAAAGAACTTCTTCCATTTGCGTGTGAAGTAGGTGGT

[0285] AGCGGTCATCATCACCATCATCATTAAAATGCAAAGCCCGCC

[0286] GAAAGGCGGGCTTTTCCTGTACTTCGCAACGATTTCGGAGTCC

[0287] GGAGACTCGCTGTTTTCGAAATTTGCGCTCAAGGGCGGGTAT

[0288] TGAACCCTACTCTGGCGTCGATGAGGGA

[0289] SEQ ID NO:38 (GamS-ZSCAN5B-6His gene fragment with adapter)

[0290] GAGGTGACGGGCCTCAAAGCCGCGTGGGAGTGAGCTAACACCGTGCGTGTTGACAATTTTACCTCTGGCGGTGATAATGGTTGCAGCTACTAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGGAAACGCTTATTACATTCAGGATCGTCTTGAGGCTCAGAGCTGGGCGCGTCACTACCAGCAGCTCGCCCGTGAAGAGAAAGAGGCAGAACTGGCAGACGACATGGAAAAAGGCCTGCCCCAGCACCTGTTTGAATCGCTATGCATCGATCATTTGCAACGCCACGGGGCCAGCAAAAAATCCATTACCCGTGCGTTTGATGACGATGTTGAGTTTCAGGAGCGCATGGCAGAACACATCCGGTACATGGTTGAAACCATTGCTCACCACCAGGTTGATATTGATTCAGAGGTAGGTGGTAGCGGTTCTGCTTGTGTTGTGGAACGGGAAGCGCTGACTCATAGTGGCAATCGCGGTGACGCACTCAATCTTAGCAGCCCCAAACGCAGCAAGCCGGACGCGTCTAGCATTAGCCAGGAAGAACCGCAGGGAGAAGCAACTCCTGTTGGCAACCGAGAATCCCCTGGGCAAGCCGAAATCAATCCTGTACACTCTCCGGGACCTGCAGGCCCCGTTTCACATCCGGATGGACAAGAGGCGAAAGCACTCCCGCCGTTCGCATGCGATGTGGGTGGTAGCGGTCATCATCACCATCATCATTAAAATGCAAAGCCCGCCGAAAGGCGGGCTTTTCTGTACTTCGCAACGATTTCGGAGTCCGGAGACTCGCTGTTTTCGAAATTTGCGCTCAAGGGCGGGTATTGAACC,837,CAATCCGCCCTCACTACAACCGGAGGTGACG GGCCTCAAAGCCGCGTGGGAGTGAGCTAACACCGTGCGTGTTGACAATTTTACCTCTGGCGGTGATAATGGTTGCAGCTACTAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGGAAACGCTTATTACATTCAGGATCGTCTTGAGGCTCAGAGCTGGGCGCGTCACTACCAGCAGCTCGCCCGTGAAGAGAAAGAGGCAGAACTGGCAGACGACATGGAAAAAGGCCTGCCCCAGCACCTGTTTGAATCGCTATGCATCGATCATTTGCAACGCCACGGGGCCAGCAAAAAATCCATTACCCGTGCGTTTGATGACGATGTTGAGTTTCAGGAGCGCATGGCAGAACACATCCGGTACATGGTTGAAACCATTGCTCACCACCAGGTTGATATTGATTCAGAGGTAGGTGGTAGCGGTTCTGCTTGTGTTGTGGAACGGGAAGCGCTGACTCATAGTGGCAATCGCGGTGACGCACTCAATCTTAGCAGCCCCAAACGCAGCAAGCCGGACGCGTCTAGCATTAGCCAGGAAGAACCGCAGGGAGAAGCAACTCCTGTTGGCAACCGAGAATCCCCTGGGCAAGCCGAAATCAATCCTGTACACTCTCCGGGACCTGCAGGCCCCGTTTCACATCCGGATGGACAAGAGGCGAAAGCACTCCCGCCGTTCGCATGCGATGTGGGTGGTAGCGGTCATCATCACCATCATCATTAAAATGCAAAGCCCGCCGAAAGGCGGGCTTTTCTGTACTTCGCAACGATTTCGGAGTCCGGAGACTCGCTGTTTTCGAAATTTGCGCTCAAGGGCGGGTATTGAACCCTACTCTGGCGTCGATGAGGGA,

[0291] SEQ ID NO:39 (GamS-ZSCAN5C-6His gene fragment, with linker)

[0292] GAGGTGACGGGCCTCAAAGCCGCGTGGGAGTGAGCTAACACCGTGCGTGTTGACAATTTTACCTCTGGCGGTGATAATGGTTGCAGCTACTAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGGAAACGCTTATTACATTCAGGATCGTCTTGAGGCTCAGAGCTGGGCGCGTCACTACCAGCAGCTCGCCCGTGAAGAGAAAGAGGCAGAACTGGCAGACGACATGGAAAAAGGCCTGCCCCAGCACCTGTTTGAATCGCTATGCATCGATCATTTGCAAC

[0293] GCCACGGGGCCAGCAAAAAATCCATTACCCGTGCGTTTGATG

[0294] ACGATGTTGAGTTTCAGGAGCGCATGGCAGAACACATCCGG

[0295] TACATGGTTGAAACCATTGCTCACCACCAGGTTGATATTGAT

[0296] TCAGAGGTAGGTGGTAGCGGTACCCCAAGCGCTTGTGTAGT

[0297] CGAAAGAGAAGCAAGTACGCACAGCGGCAATCGGGGGGACG

[0298] CCTTGAACTTGTCTTCTCCTAAAAGATCGAAGCCCGATGCGT

[0299] CATCAATTAGCCAGGAAGAACCACAGGGTGAAGCGACACCG

[0300] GTAGGCAATAGAGAGTCTCCTGGACAAGCCGGAATGAACTC

[0301] GATCCATTCCCCGGGCCCAGCATCACCGGTGAGCCACCCGG

[0302] ATGGCCAGGAGGCGAAGGCCCTGCCACCATTTGCCTGCGAT

[0303] GTTGGTGGTAGCGGTCATCATCACCATCATCATTAAAATGCA

[0304] AAGCCCGCCGAAAGGCGGGCTTTTCTGTACTTCGCAACGATT

[0305] TCGGAGTCCGGAGACTCGCTGTTTTCGAAATTTGCGCTCAAG

[0306] GGCGGGTATTGAACC,843,CAATCCGCCCTCACTACAACCGGA

[0307] GGTGACGGGCCTCAAAGCCGCGTGGGAGTGAGCTAACACCG

[0308] TGCGTGTTGACAATTTTACCTCTGGCGGTGATAATGGTTGCA

[0309] GCTACTAATAATTTTGTTTAACTTTAAGAAGGAGATATACCAT

[0310] GGGAAACGCTTATTACATTCAGGATCGTCTTGAGGCTCAGAG

[0311] CTGGGCGCGTCACTACCAGCAGCTCGCCCGTGAAGAGAAAG

[0312] AGGCAGAACTGGCAGACGACATGGAAAAAGGCCTGCCCCAG

[0313] CACCTGTTTGAATCGCTATGCATCGATCATTTGCAACGCCAC

[0314] GGGGCCAGCAAAAAATCCATTACCCGTGCGTTTGATGACGAT

[0315] GTTGAGTTTCAGGAGCGCATGGCAGAACACATCCGGTACAT

[0316] GGTTGAAACCATTGCTCACCACCAGGTTGATATTGATTCAGA

[0317] GGTAGGTGGTAGCGGTACCCCAAGCGCTTGTGTAGTCGAAA

[0318] GAGAAGCAAGTACGCACAGCGGCAATCGGGGGGACGCCTTG

[0319] AACTTGTCTTCTCCTAAAAGATCGAAGCCCGATGCGTCATCA

[0320] ATTAGCCAGGAAGAACCACAGGGTGAAGCGACACCGGTAGG

[0321] CAATAGAGAGTCTCCTGGACAAGCCGGAATGAACTCGATCCA

[0322] TTCCCCGGGCCCAGCATCACCGGTGAGCCACCCGGATGGCC

[0323] AGGAGGCGAAGGCCCTGCCACCATTTGCCTGCGATGTTGGT

[0324] GGTAGCGGTCATCATCACCATCATCATTAAAATGCAAAGCCC

[0325] GCCGAAAGGCGGGCTTTTCTGTACTTCGCAACGATTTCGGAG

[0326] TCCGGAGACTCGCTGTTTTCGAAATTTGCGCTCAAGGGCGGG

[0327] TATTGAACCCTACTCTGGCGTCGATGAGGGA

[0328] Epitope from ZSCAN5A, SEQ ID NO:40

[0329] TPSACVVEREASTHSGNRGDALNLSSPKRSKPDASSISQEEPQGEATPVGNRESPGQAGMNSIHSPGPASPVSHPDGQEAKALPPFACDV

[0330] Epitope from ZSCAN5B, SEQ ID NO:41

[0331] SACVVEREALTHSGNRGDALNLSSPKRSKPDASSISQEEPQGEATPVGNRESPGQAEINPVHSPGPAGPVSHPDGQEAKALPPFACDVC

[0332] Epitope from ZSCAN5C of SEQ ID NO:42

[0333] TPSACVVEREASTHSGSRGDALNLRGLKRSKPDATSISQEEPQGEATPVGNRESPGQAEINPVHSPGPAGPVSHPSGQEVKELLPFACEV

[0334] SEQ ID NO:43 (Immunoglobulin heavy chain constant alpha 1)

[0335] ASPTSPKVFPLSLCSTQPDGNVVIACLVQGFFPQEPLSVTWSESGQGVTARNFPPSQDASGDLYTTSSQLTLPATQCLAGKSVTCHVKHYTNPSQDVTVPCPVPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASGVTFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVDGTCY

[0336] SEQ ID NO:44 (Immunoglobulin heavy chain constant alpha 2)

[0337] ASPTSPKVFPLSLDSTPQDGNVVVACLVQGFFPQEPLSVTWSESGQNVTARNFPPSQDASGDLYTTSSQLTLPATQCPDGKSVTCHVKHYTNSSQDVTVPCRVPPPPPCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASGATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTANITKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTYAVTSILRVAAEDWKKGETFSCMVGHEALPLAFTQKTIDRMAGKPTHINVSVVMAEADGTCY

[0338] SEQ ID NO:45(Immunoglobulin heavy chain constant delta)

[0339] APTKAPDVFPIISGCRHPKDNSPVVLACLITGYHPTSVTVTWYMGTQSQPQRTFPEIQRRDSYYMTSSQLSTPLQQWRQGEYKCVVQHTASKSKKEIFRWPESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEERETKTPECPSHTQPLGVYLLTPAVQDLWLRDKATFTCFVVGSDLKDAHLTWEVAGKVPTGGVEEGLLERHSNGSQSQHSRLTLPRSLWNAGTSVTCTLNHPSLPPQRLMALREPAAQAPVKLSLNLLASSDPPEAASWLLCEVSGFSPPNILLMWLEDQREVNTSGFAPARPPPQPRSTTFWAWSVLRVPAPPSPQPATYTCVVSHEDSRTLLNASRSLEVSYVTDHGPMK

[0340] SEQ ID NO:46(Immunoglobulin heavy chain constant epsilon)

[0341] ASTQSPSVFPLTRCCKNIPSNATSVTLGCLATGYFPEPVMVTWDTGSLNGTTMTLPATTLTLSGHYATISLLTVSGAWAKQMFTCRVAHTPSSTDWVDNKTFSVCSRDFTPPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTINITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRL EVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGK

[0342] SEQ ID NO:47 (Immunoglobulin heavy chain constant gamma 1)

[0343] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0344] SEQ ID NO:48 (Immunoglobulin heavy chain constant gamma 2)

[0345] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0346] SEQ ID NO:49 (Immunoglobulin heavy chain constant gamma 3 OS)

[0347] ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPGK

[0348] SEQ ID NO:50 (Immunoglobulin heavy chain constant gamma 4)

[0349] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

[0350] SEQ ID NO:51(Immunoglobulin heavy chain constant mu)

[0351] GSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFSWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVMQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVPPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLGQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLPSPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTGKPTLYNVSLVMSDTAGTCY

[0352] SEQ ID NO:52(Immunoglobulin lambda constant 1)

[0353] GQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS

[0354] SEQ ID NO:53 (Immunoglobulin lambda constant 2)

[0355] GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS

[0356] SEQ ID NO:54 (Immunoglobulin lambda constant 3)

[0357] GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS

[0358] SEQ ID NO:55 (Immunoglobulin lambda constant 6)

[0359] GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVKVAWKADGSPVNTGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPAECS

[0360] SEQ ID NO:56 (Immunoglobulin lambda constant 7)

[0361] GQPKAAPSVTLFPPSSEELQANKATLVCLVSDFNPGAVTVAWKADGSPVKVGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCRVTHEGSTVEKTVAPAECS

[0362] SEQ ID NO:57 (Immunoglobulin kappa constant)

[0363] RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Example

[0364] Overview

[0365] method : Four patients with neurological conditions (P1-4) underwent serological examination. For this purpose, comprehensive autoantibody screening was performed on patient sera by indirect immunofluorescence assay (IIFA) using neuronal tissue sections or HEK293 cells expressing recombinant neuronal antigens. Autoantigens were identified using PhIP-Seq analysis performed with four sera showing similar fluorescence patterns on neuronal tissue IIFA, which was validated by recombinant expression of the target antigen in HEK293 cells and the use of recombinant proteins in immunoassays. In addition, serum or CSF of patients (n=68) with neurological symptoms and reactivity similar to PS1-4 on neuronal tissue sections and healthy control sera (n=50) were analyzed in a recombinant cell-based indirect immunofluorescence assay (RC-IIFA) using HEK293 cells expressing ZSCAN5B. 49 serum samples from patients with different neuronal autoantibodies (9× anti-neuronal chondroitin positive, 10× anti-Ri positive, 10× anti-GAD65 positive, 10× anti-Yo positive, 10× anti-ITPR1 positive) were analyzed in RC-IIFA using ZSCAN5B but did not show positive reactions. Sera with positive reactions in RC-IIFA were analyzed by Western blotting using lysates of HEK293 cells recombinantly expressing ZSCAN5B, and the results were confirmed by Western blotting using recombinant ZSCAN5B purified from Escherichia coli cells overexpressing ZSCAN5B. In addition, epitopes containing protein fragments from ZSCAN5A, ZSCAN5B, and ZSCAN5C were produced in a cell-free expression system and analyzed by Western blotting using index serum.

[0366] result: IIFA screening with patient sera (PS1-4) showed IgG reactivity to the molecular and granular layers of the monkey cerebellum. In addition, no IgG reactivity was found to a panel of 30 recombinantly expressed established neural autoantigens. In PhIP-Seq analysis, PS1-4 bound to peptides of ZSCAN5B and ZSCAN5C, and PS1 and 3 additionally to peptides of ZSCAN5A. In RC-IIFA using HEK293 cells expressing ZSCAN5B, all four patient sera showed positive reactions, which were not observed in 50 healthy control sera and 49 control samples with other neuronal autoantibodies. In addition, 20 of the analyzed sera of 68 patients with similar fluorescence reactivity compared to PS1-4 on neuronal tissue sections were positive for anti-ZSCAN5B. Positive reactions were also observed for patient sera in immunoblots using recombinant ZSCAN5B-His, but not for control sera. Similar Western blot reactivity was observed for all index sera and epitopes containing protein fragments from ZSCAN5A, ZSCAN5B, and ZSCAN5C.

[0367] Clinical data were available for eight anti-ZSCAN5B-positive patients. They had encephalitis (3x), paraneoplastic syndrome (1x), dementia (1x), neuromyelitis optica spectrum disorder (2x), or neuromyotonia (1x). In the case of the diagnosis of neuromyotonia, additional low-titer anti-VGKC antibodies were detected by RIA during routine diagnostic workup.

[0368] method

[0369] patient

[0370] All patient samples were sent to the Clinical Immunological Laboratory Lübeck (Germany) for autoantibody detection. Subsequently, they were anonymized and provided to the authors. The control group included sera from 50 healthy donors and sera from 49 patients with different neuronal autoantibodies.

[0371] Indirect immunofluorescence assay (IFA)

[0372] IFA was performed using mosaic biochips with cryosections of brain tissue (cerebellum of rat and monkey, hippocampus of rat, thalamus) and slides of recombinant HEK293 cells expressing 30 different neuronal antigens: Hu, Yo, Ri, CV2, PNMA2, ITPR1, Homer 3, CARP VIII, ARHGAP26, ZIC4, DNER / Tr, GAD65, GAD67, amphoterin, recoverin, GABAB receptors, glycine receptors, DPPX, IgLON5, glutamate receptors (NMDA, AMPA, mGluR1, mGluR5, GLURD2 types), LGI1, CASPR2, AQP4 (M1 and M23), MOG, ATP1A3, NCDN (EUROIMMUN, FA 111a-1003-51, FA 1112-1003-50, FA-1128-1003-50, FA112d-1003-1, FA 112m-1003-50, FA 1151-1003-50, Miske R, Hahn S, Rosenkranz T, Müller M, Dettmann IM, Mindorf S, Denno Y, Brakopp S, Scharf M,Teegen B,Probst C,Melzer N,Meinck HM,Terborg C, W,Komorowski L.,2016,Autoantibodies against glutamatereceptorδ2after allogenic stem cell transplantation.Neurol NeuroimmunolNeuroinflamm.,3(4):e255;Scharf M,Miske R,Heidenreich F,Giess R,Landwehr P, IM,Begemann N,Denno Y,Tiede S, C,Schlumberger W,Unger M,Teegen B, W,Probst C,Komorowski L,2015,Neuronal Na+ / K+ATPase is anautoantibody target in paraneoplastic neurologic syndrome,Neurology;84(16):1673-9;Miske R,Gross CC,Scharf M,Golombeck KS,Hartwig M,Bhatia U,Schulte-Mecklenbeck A, K, Strippel C, L,Synofzik M,Lohmann H,Dettmann IM,Deppe M,Mindorf S,Warnecke T,Denno Y,Teegen B,Probst C,Brakopp S,WandingerKP,Wiendl H, W, Meuth SG, Komorowski L, Melzer N, 2016, Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration, Neurol Neuroimmunol Neuroinflamm.; 4 (1): e307)). Each biochip array was incubated with serum or CSF diluted in PBS for 30 minutes, washed with PBS-Tween and immersed in PBS-Tween for 5 minutes. Subsequently, fluorescein isothiocyanate (FITC)-labeled goat anti-human IgG (EUROIMMUN Medizinische Labordiagnostika AG, Luebeck Germany) or Alexa488-labeled goat anti-human IgG (1:500, Jackson Research, Suffolk, United Kingdom) was applied for 30 minutes. Another washing step was performed with PBS-Tween, and the slides were embedded in PBS-buffered glycerol containing DABCO and analyzed by fluorescence microscopy. Reactivity is classified as positive or negative based on the fluorescence intensity of transfected cells in direct comparison with untransfected cells and control samples. The endpoint titer refers to the last dilution that shows visible fluorescence.

[0373] In the competitive inhibition experiment, serum diluted 1:32 in PBS-Tween was pre-incubated with HEK293 cell lysates expressing recombinant ZSCAN5B or HEK293 cell lysates transfected with empty vector as control at 1:2 in PBS-Tween for 1 hour, and then they were incubated in IFA on neuronal tissue sections. Cell nuclei were observed by DNA staining using TO-PRO-3 iodide (1:2000, ThermoFisher Scientific, Dreieich, Germany). The results were evaluated by two independent observers using a laser scanning microscope (LSM700, Zeiss, Jena, Germany) or a EUROStarII microscope (EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany). All incubation steps were performed at room temperature.

[0374] PhIP-Seq analysis

[0375] PhIP-Seq analysis using four sera showing similar fluorescence patterns on neuronal tissue IIFA was used to identify targets of autoantibodies. PhIP-Seq analysis was performed at CDI Laboratories, Inc (Mayaguez, USA) using the HuScan (Human Proteome Phage Display) method using four patient sera (patients 1–4) showing similar staining patterns in tissue indirect immunofluorescence assay (IIFA) on primate cerebellum and 20 control sera showing different antibody binding patterns in neuronal tissue IIFA. A hit list showing the results was generated.

[0376] Recombinant expression of full-length human ZSCAN5B and ZSCAN5B-His (protein 5B containing zinc finger and SCAN domains) in HEK293:

[0377] Two synthetic gene fragments encoding human ZSCAN5B were obtained from IDT (Integrated DNA Technologies, Inc.).

[0378] The first fragment encodes amino acids 1-242 of human ZSCAN5B, and the other fragment encodes amino acids 243-495 of human ZSCAN5B, including the stop codon. The two gene synthesis products were re-amplified by PCR to produce 747 bp fragment-1 and 793 bp fragment-2 (SEQ ID NO: 25 and SEQ ID NO: 26). Both PCR fragments were gel purified and digested with Esp3I (New England Biolabs, R0734).

[0379] The third fragment of ZSCAN5B was amplified by PCR using the gene synthesis product (SEQ ID NO: 26) as a template and DNA oligonucleotide primers sense ZSCAN5B-F3 (SEQ ID NO: 27) and antisense ZSCAN5B-F3 (SEQ ID NO: 28), generating ZSCAN5B PCR fragment-3 without a stop codon (SEQ ID NO: 29). The amplified product was digested with Esp3I (New England Biolabs, R0734). The Esp3I digested fragments of SEQ ID NO: 25 and SEQ ID NO: 26 were ligated with the pTriEx-1 vector (Merck, Darmstadt, Germany) linearized with NcoI and XhoI to generate SEQ ID NO: 30, encoding ZSCAN5B [human] (SEQ ID NO: 31). The Esp3I digested fragments of SEQ ID NO:25 and SEQ ID NO:29 were also ligated with the NcoI and XhoI linearized pTriEx-1 vector (Merck, Darmstadt, Germany) to generate SEQ ID NO:32, which encodes ZSCAN5B [Human] (SEQ ID NO:33) fused to a C-terminal octa-histidine tag (H8).

[0380] ZSCAN5B-His or dHis was expressed in human HEK293 cells following ExGen500-mediated transfection (ThermoFisher Scientific, Schwerte, Germany) according to the manufacturer's instructions. To prepare the substrate for IFA, HEK293 cells were seeded on sterile coverslips, transfected, and allowed to express ZSCAN5B for 48 hours. The coverslips were washed with PBS, fixed with acetone for 10 minutes at room temperature, air-dried, cut into millimeter-sized biochips, and used as substrates in IFA as described. Alternatively, cells were transfected into standard T-flasks and harvested after 5 days. The cell pellet was extracted with lysis buffer. The extract was stored in aliquots at -80°C until further use. To purify ZSCAN5B-His, the recombinant antigen was expressed in Escherichia coli cells and enriched by immobilized metal ion affinity chromatography combined with cation exchange chromatography.

[0381] Cell-free protein expression of GamS-ZSCAN5A-6His, GamS-ZSCAN5B-6His, and GamS-ZSCAN5C-6His:

[0382] Three linear gene fragments containing epitope regions of ZSCAN5A, ZSCAB5B and ZSCAN5C were designed for use in the E. coli cell-free protein synthesis system (myTXTL linear DNA expression kit, arbor bioscience).

[0383] GamS is a 12 kDa bacterial nuclease inhibitor that is well expressed in the "myTXTL Linear DNA Expression Kit" and was used as an N-terminal fusion partner to increase the molecular weight of each construct for easy detection by western blot. In addition, a C-terminal 6His tag was added to each construct.

[0384] The resulting constructs, GamS-ZSCAN5A-6His (SEQ ID NO:34), GamS-ZSCAN5B-6His (SEQ ID NO:35), and GamS-ZSCAN5C-6His (SEQ ID NO:36), were ordered from Twist Bioscience (South San Francisco, USA) with additional 3' and 5' DNA sequences specific to the E. coli sigma70 promoter and terminator required for the transcription and translation machinery of the E. coli myTXTL Linear DNA Expression Kit (GamS-ZSCAN5A-6His gene fragment with adapter (SEQ ID NO:37), GamS-ZSCAN5B-6His gene fragment with adapter (SEQ ID NO:38), and GamS-ZSCAN5C-6His gene fragment with adapter (SEQ ID NO:39).

[0385] Protein expression was performed according to Daicel Arbor Biosciences "myTXTL Linear DNA Expression Kit" protocol (arbor bioscience). 9uL cell-free expression mixture in 1.5mL Eppendorf tubes was mixed with 3uL 80nM dsDNA and incubated at 29°C for 16 hours. After incubation, 400μL wash buffer (20mM HEPES, pH8, 300mM NaCl, 20mM imidazole) and 30μL His magnetic beads (Cube Biotech Biocube, Monheim, Germany) were added to each expression mixture and incubated for 30 minutes. The magnetic beads were washed twice in wash buffer in a magnetic stand. Protein was eluted in 100μl elution buffer (20mM HEPES, pH8, 300mM NaCl, 500mM imidazole), and then exchanged into PBS with a rotating desalting column (zeba, ThermoFisher Scientific, Schwerte, Germany) buffer.

[0386] Immunoblotting

[0387] HEK-ZSCAN5B-His fraction, ZSCAN5B-His fraction purified from E. coli or ZSCAN-6His fraction were separated by SDS-PAGE (NuPAGE, ThermoFisher Scientific, Schwerte, Germany) and subsequently electrotransferred to nitrocellulose membrane by slot blotting using transfer buffer (ThermoFisher Scientific, Schwerte, Germany) according to the manufacturer's instructions. The membrane was blocked with 1:5 diluted blotting wash buffer casein (EUROIMMUN, Germany) for 15 min and incubated with diluted patient or control sera (diluted 1:200) in blotting wash buffer casein for 3 h, followed by 3 washing steps with universal blotting buffer (EUROIMMUN Medizinische Labordiagnostika AG, Lübeck), a 30 min second incubation with anti-human IgG-AP (EUROIMMUN Medizinische Labordiagnostika AG, Lübeck), 3 washing steps, and staining with NBT / BCIP substrate (EUROIMMUN Medizinische Labordiagnostika AG, Lübeck). If not otherwise stated, reagents were purchased from Merck, Darmstadt, Germany or Sigma-Aldrich, Heidelberg, Germany.

[0388] result

[0389] Characterization of patient autoantibodies

[0390] Indirect immunofluorescence assay (IIFA) using permeabilized cerebellar cryosections from rats and primates and serum from patients 1-4 (PS1-4) showed dotted staining in the granular layer and granular staining in the molecular layer ( Figure 1 Further monospecific analysis using recombinant HEK293 cells expressing 30 neural autoantigens (Hu, Yo, Ri, CV2, PNMA2, SOX1, ITPR1, Homer 3, CARP VIII, ARHGAP26, ZIC4, DNER / Tr, GAD65, GAD67, amphoterin, recoverin, GABAB receptors, glycine receptors, DPPX, IgLON5, glutamate receptors [NMDA, AMPA, mGluR1, mGluR5, GLURD2 types], LGI1, CASPR2, AQP4 [M1 and M23], MOG, ATP1A3, and NCDN) did not show positive reactions.

[0391] Identification of ZSCAN5B, ZSCAN5C, and ZSCAN5A as targets of neuronal autoantibodies

[0392] Patient sera 1-4 bound to peptides from human ZSCAN5B (protein 5B containing zinc fingers and SCAN domains, Uniprot acc. #A6NJL1) and ZSCAN5C (protein 5C containing zinc fingers and SCAN domains, Uniprot acc. #A6NGD5) in the PhIP-Seq analysis. PS1 and 3 additionally bound to peptides from ZSCAN5A (protein 5A containing zinc fingers and SCAN domains, Uniprot acc. #Q9BUG6) (Table 1). None of the 20 control sera that showed different staining patterns in IIFA of neuronal tissue bound to peptides from one of the three proteins ZSCAN5B, ZSCAN5C, or ZSCAN5A. All four patient sera bound to the same peptides from ZSCAN5B as well as to peptides from homologous regions in ZSCAN5C and ZSCAN5A ( Figure 2 ), indicating that the epitopes detected by the patient sera may be located at amino acid residues 272–360 in ZSCAN5B and amino acid residues 271–360 in ZSCAN5C and ZSCAN5A.

[0393] Table 1. PhIP-Seq analysis results.

[0394] PhIP-Seq analysis results for ZSCAN5A, ZSCAN5B, and ZSCAN5C are summarized for serum samples from patients 1–4. HuScan scores and hit numbers are given for all four index patient samples.

[0395]

[0396] Neutralization of staining patterns in neuronal tissue

[0397] The neural tissue IIFA reactivity of patient 3's autoantibodies could be eliminated by pre-incubating patient 3's serum with HEK293 lysate containing ZSCAN5B-His (SEQ ID NO: 10). Figure 3 ).

[0398] Detection of anti-ZSCAN5A, anti-ZSCAN5B and anti-ZSCAN5C autoantibodies in immunoassays using recombinant full-length ZSCAN5B and epitope-containing protein fragments of ZSCAN5A, ZSCAN5B and ZSCAN5C

[0399] In a recombinant cell-based IIFA (RC-IIFA) with HEK293-ZSCAN5B and HEK293-ZSCAN5B-His cells (SEQ ID NO:8 and SEQ ID NO:10), PS1-4 reacted with HEK293-ZSCAN5B and HEK293-ZSCAN5B-His (endpoint titers 1:3200, 1:1000, 1:10, 1:3200), but not with empty vector-transfected HEK cells ( Figure 4 ). In addition, 20 of the 68 patient sera that showed similar reactivity to PS1-4 in IFA using neuronal tissue sections showed positive reactions in RC-IIFA using HEK293-ZSCAN5B and HEK293-ZSCAN5B-His cells, while none of the 50 sera from healthy donors showed similar reactivity (1:10 dilution). No positive reactions were observed for sera from 49 patients with different neuronal autoantibodies (9x anti-neurochondroitin positive, 10x anti-Ri positive, 10x anti-GAD65 positive, 10x anti-Yo positive, 10x anti-ITPR1 positive). CSF was obtained from 2 patients with positive serum reactions in RC-IIFA. Both CSFs were negative in neuronal tissue IIFA but showed positive reactions in RC-IIFA using HEK293-ZSCAN5B cells (endpoint titer 1:1 or 1:3,2).

[0400] Immunoblotting was performed using recombinant HEK293-ZSCAN5B-His lysate and the results were confirmed using ZSCAN5B-His purified from E. coli. Expression of the recombinant 57 kDa ZSCAN5B-His protein was demonstrated using an anti-His-tag antibody. Incubation of 13 patient sera with 15 healthy control sera showed strong reactions of all 13 patient sera with the recombinant protein, while none of the 15 healthy control sera showed similar reactions ( Figure 5 A).

[0401] Clinical data for patients 4-11 are available and are summarized in Table 2. In addition, epitope-containing protein fragments of ZSCAN5A, ZSCAN5B, and ZSCAN5C were analyzed using patient sera PS1-4 and anti-His tag antibodies as controls. GamS-ZSCAN5A(271-360)-His, GamS-ZSCAN5B(272-360)-His, and GamS-ZSCAN5C(271-360)-His were detected with similar intensities in all four analyzed patient sera. Figure 5 B).

[0402] Table 2. Clinical manifestations.

[0403] Clinical information was available for eight patients. Serum endpoint titers are listed. CSF was also available from one patient.

[0404]

[0405]

[0406] Using IIFA, autoantibodies against ZSCAN5B were found in an additional 37 patients, some of whom had at least one of epilepsy, encephalitis (e.g., autoimmune encephalitis and limbic encephalitis), dementia, cognitive decline, ataxia, neuropathy, and paraneoplastic syndrome.

Claims

1. A method comprising the step of detecting mammalian antibodies that specifically bind to ZSCAN5 in a sample.

2. A method for isolating a mammalian antibody that specifically binds to ZSCAN5, the method comprising: The following steps are involved: a) immobilizing at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof on a carrier, b) contacting a sample comprising the antibody with said at least one polypeptide under conditions compatible with formation of a complex, wherein said antibody binds to said polypeptide, c) separating the complex formed in step a) from the sample, d) optionally separating the antibody from the polypeptide, and e) optionally detecting the antibody or complex.

3. A method, wherein include: contacting a polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof with a liquid comprising a mammalian antibody that specifically binds to ZSCAN5, wherein a candidate drug is present and / or the liquid does not contain a sample from a subject to be diagnosed, and Binding of the antibody is preferably detected in a quantitative manner.

4. A mammalian antibody that specifically binds to ZSCAN5, preferably in a liquid comprising one or more, more preferably all, selected from the group comprising an artificial buffer, a preservative and an artificial anticoagulant and / or selected from the group comprising blood, such as whole blood, plasma, serum and CSF, optionally wherein the liquid is diluted.

5. A carrier comprising a solid phase containing at least one immobilized polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof, and a) a negative control and / or a positive control and / or b) at least one further diagnostically useful antigen, wherein the at least one immobilized polypeptide and the negative control and / or the positive control or the further antigen are spatially separated on the carrier, Or a first carrier having a solid phase containing at least one immobilized polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof, and a second carrier comprising a solid phase comprising immobilized a) a negative control and / or a positive control and / or b) at least one additional polypeptide comprising an immobilized antigen or a variant thereof.

6. The carrier according to claim 5, wherein the at least one additional antigen is at least one antigen selected from NMDAR, LgI1, AMPA1, AMPA2, CASPR2, GABA B, GABA A, DPPX, IGLON5, Hu, Yo, CV2 / CRMP5, Ri, Ma2, amphoterin, recovery protein, RGS8, DAGLA, STX1B, AK5, AP3B2, raft protein 1+2, GRM1, GRM2, GRM5, GLURD2, ITPR1, KCNA2, NCDN, septin 3+5+6+7+11, Sez6L2 or variants thereof, preferably all antigens.

7. A kit comprising at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof and a carrier, preferably a carrier according to any one of claims 5 to 6, wherein a) immobilizing at least one polypeptide on a carrier, preferably a carrier according to any one of claims 5 to 6, and the kit further comprises means for detecting mammalian antibodies, b) the at least one polypeptide and the carrier are configured to immobilize the at least one polypeptide on the surface of the carrier, preferably via an affinity tag and a ligand that binds to the affinity tag, and the kit further comprises means for detecting mammalian antibodies, c) the carrier is immobilized with means for capturing antibodies, and the kit further comprises means for detecting mammalian antibodies, preferably comprising at least one detectably labeled polypeptide, or d) the support and the means for capturing antibodies are configured to immobilize the means for capturing antibodies on the surface of the support, preferably via an affinity tag and a ligand that binds to the affinity tag, and the kit further comprises means for detecting mammalian antibodies, preferably comprising at least one detectably labeled polypeptide, And preferably one or more selected from a recombinant antibody that binds to ZSCAN5, a mammalian antibody that binds to ZSCAN5, a chemical solution that reacts with a detectable label, a positive control, a negative control, a waterproof container for incubating a sample with a carrier or a reagent, a sample dilution buffer, a washing buffer, and a calibrator, preferably a set of calibrators, more preferably all.

8. Use of the following for identifying a patient at increased risk of having or developing a disease associated with the presence of a mammalian antibody that specifically binds to ZSCAN5: a) a mammalian antibody that specifically binds to ZSCAN5 or a variant thereof; or b) at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof in combination with means for detecting antibodies in a mammal; or c) a carrier according to any one of claims 5 to 6; or d) The kit according to claim 7.

9. Use of at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof, or a mammalian antibody that specifically binds to ZSCAN5 or a variant thereof, or a recombinant antibody that specifically binds to ZSCAN5 or a variant thereof for the manufacture of an analytical kit or a medical device.

10. Use of a mammalian antibody that specifically binds to ZSCAN5 or a variant thereof or a recombinant antibody that specifically binds to ZSCAN5 or a variant thereof as a positive control for detecting antibodies that specifically bind to ZSCAN5 or a variant thereof in a sample, wherein the antibody is preferably recognized by a secondary antibody against mammalian IgG class immunoglobulins.

11. An ex vivo method for removing mammalian antibodies that specifically bind to ZSCAN5 or a variant thereof from the blood of a mammalian patient.

12. The method according to any one of claims 2-3, the carrier according to any one of claims 5-6, the kit according to claim 7 or the use according to claim 8 or 9, wherein the polypeptide is a recombinant, isolated and / or purified polypeptide.

13. The method according to any one of claims 1-3 and 12, the kit according to claim 7 or 12, or the use according to any one of claims 8-10 and 12, wherein the sample is selected from the group comprising whole blood, plasma, serum, cerebrospinal fluid and saliva.

14. The method according to any one of claims 1-3 and 11-13, the kit according to any one of claims 7 and 12-13 or the use according to any one of claims 8-10 and 12-13, wherein the antibody or complex is detected using a detection method selected from the group consisting of immunodiffusion, electrophoresis, light scattering immunoassay, agglutination, labeled immunoassay such as selected from radiolabeled immunoassay, enzyme immunoassay, more preferably ELISA, chemiluminescent immunoassay, preferably electrochemiluminescent immunoassay and immunofluorescence, preferably indirect immunofluorescence.

15. The method according to any one of claims 1 to 3 and 12 to 14, the carrier according to any one of claims 5 to 6 and 12, the kit according to any one of claims 7 to 12 to 14 or the use according to any one of claims 8 to 10 to 12 to 14, wherein the carrier is selected from the group consisting of slides, preferably slides for microscopy, biochips, microtiter plates, lateral flow devices, test strips, membranes, preferably line blots, chromatography columns and beads, preferably magnetic beads or fluorescent beads.

Citation Information

Patent Citations

  • Cellulose-based immunoadsorber

    EP3477300A1

  • V-like domain binding molecules

    US7166697B1

  • Small cell lung cancer associated antigens and uses therefor

    US7314721B2

Cited By

  • Protein for human body P / Q type VGCC autoantibody detection and application

    CN122103307A

  • A protein for the detection of P / Q type VGCC autoantibodies in humans and its application

    CN122103307B